Artykuły w czasopismach: „Sheng yun xue”

1

Jhang, Jing-Siang, Hanoch Livneh, Shu-Yi Yang, Hui-Ju Huang, Michael W. Y. Chan, Ming-Chi Lu, Chia-Chou Yeh i Tzung-Yi Tsai. "Decreased risk of colorectal cancer among patients with type 2 diabetes receiving Chinese herbal medicine: a population-based cohort study". BMJ Open Diabetes Research & Care 8, nr 1 (marzec 2020): e000732. http://dx.doi.org/10.1136/bmjdrc-2019-000732.

Pełny tekst źródła

Streszczenie:

ObjectivesPatients with type 2 diabetes have a higher risk of colorectal cancer (CRC), but whether Chinese herbal medicines (CHMs) can reduce this risk is unknown. This study investigated the effect that CHMs have on CRC risk in patients with type 2 diabetes.Research design and methodsThis cohort study used the Taiwanese National Health Insurance Research Database to identify 54 744 patients, newly diagnosed with type 2 diabetes, aged 20–70 years, who were receiving treatment between 1998 and 2007. From this sample, we randomly selected 14 940 CHMs users and 14 940 non-CHMs users, using propensity scores matching. All were followed through 2012 to record CRC incidence. Cox proportional hazards regression was used to compute the hazard ratio (HR) of CRC by CHMs use.ResultsDuring follow-up, 235 CHMs users and 375 non-CHMs users developed CRC, incidence rates of 1.73% and 2.47% per 1000 person-years, respectively. CHM users had a significantly reduced risk of CRC compared with non-CHM users (adjusted HR=0.71; 95% CI 0.60 to 0.84). The greatest effect was in those receiving CHMs for more than 1 year. Huang-Qin, Xue-Fu-Zhu-Yu-Tang, Shu-Jing-Huo-Xue-Tang, Liu-Wei-Di-Huang-Wan, Ji-Sheng-Shen-Qi-Wan, Gan-Lu-Yin, Shao-Yao-Gan-Cao-Tang and Ban-Xia-Xie-Xin-Tang were significantly associated with lower risk of CRC.ConclusionIntegrating CHMs into the clinical management of patients with type 2 diabetes may be beneficial in reducing the risk of CRC.

Style APA, Harvard, Vancouver, ISO itp.

2

Starostina, A. B. "Daoist priest as magical helper in Pei Xing’s novella “The Tale of Xue Zhao”". Orientalistica 6, nr 3-4 (19.11.2023): 691–704. http://dx.doi.org/10.31696/2618-7043-2023-6-3-4-691-704.

Pełny tekst źródła

Streszczenie:

The article aims to confirm the hypothesis presented in 2011 that the chuanqi tale “Xue Zhao” by Pei Xing (9th century) contains a sequence of motifs characteristic of the international tale type “Sleeping Beauty” (no. 410 in the Aarne – Thompson Index). The role of the Daoist Celestial master Shen (Shen Yuan / Shen Yuanzhi) as a helper is considered. The author provides some data on the image of Master Shen as the companion of Emperor Xuanzong on his lunar journey in Tang fiction. The article proves the existence of parallel characters to Shen Yuan in the early Western European versions of “Sleeping Beauty”.

Style APA, Harvard, Vancouver, ISO itp.

3

Tseng, Chu-Yao, Ching-Wen Huang, Hsin-Chia Huang i Wei-Chen Tseng. "Utilization Pattern of Traditional Chinese Medicine among Fracture Patients: A Taiwan Hospital-Based Cross-Sectional Study". Evidence-Based Complementary and Alternative Medicine 2018 (30.09.2018): 1–9. http://dx.doi.org/10.1155/2018/1706517.

Pełny tekst źródła

Streszczenie:

Traditional Chinese medicine (TCM) divides fracture treatment into three stages. Many TCM herbs and formulas have been used to treat fractures for thousands of years. However, research regarding the Chinese herbal products (CHPs) that should be used at different periods of treatment is still lacking. This study aims to identify the CHPs that should be used at different periods of treatment as well as confirm the TCM theory of fracture periods medicine. We used prescriptions of TCM outpatients with fracture diagnoses analyzed using the Chang Gung Research Database (CGRD) from 2000 to 2015. According to the number of days between the date of the fracture and the clinic visit date, all patients were assigned to one of three groups. Patients with a date gap of 0-13 days were assigned to the early period group; those with a date gap of 14-82 days were assigned to the middle period group; and those with a date gap of 83-182 days were assigned to the late period group. We observed the average number of herbal formulas prescribed by the TCM doctor at each visit was 2.78, and the average number of single herbs prescribed was 6.47. The top three prescriptions in the early fracture period were Zheng-gu-zi-jin-dang, Shu-jing-huo-xue-tang, and Wu-ling-san. In the middle fracture period, the top three formulas were Zheng-gu-zi-jin-dang, Shu-jing-huo-xue-tang, and Zhi-bai-di-huang-wan. In the late fracture period, the top three formulas were Shu-jing-huo-xue-tang, Gui-lu-er-xian-jiao, and Du-huo-ji-sheng-tang. The main single herbs used in the early fracture period were Yan-hu-suo, Gu-sui-bu, and Dan-shen. From the middle to the late period, the most prescribed single herbs were Xu-duan, Gu-sui-bu, and Yan-hu-suo. We concluded that the results showed that the CGRD utilization pattern roughly meets the TCM theory at different fracture periods.

Style APA, Harvard, Vancouver, ISO itp.

4

Tian, Xiaofei. "Representing Kingship and Imagining Empire in Southern Dynasties Court Poetry". T’oung Pao 102, nr 1-3 (3.10.2016): 18–73. http://dx.doi.org/10.1163/15685322-10213p03.

Pełny tekst źródła

Streszczenie:

Before the fifth century, the imperial identity of a ruler seems to have disabled him as a writer rather than encouraged him to be more prolific. Literary production gradually became centered in the court by the mid-fifth century, and a distinct feature of Southern Dynasties literature is the phenomenon that emperors and princes joined with their courtiers in the act of writing poetry on social occasions. This paper focuses on a number of poems by Emperor Wen of the Song (r. 424-453), Yan Yanzhi (384-456), Xie Tiao (464-499), Shen Yue (441-513), and Liu Xiaochuo (481-539) that represent kingship and empire and thereby become a means of disseminating and implementing imperial power. In particular, it examines the physical and discursive construction of the capital Jiankang. We see thereby that Southern Dynasties court poetry was instrumental in the performance of sovereignty and the envisioning of the new, southern empire. Avant le Ve siècle, le fait d’accéder au titre d’empereur semble avoir réduit ceux à qui cela arrivait à l’incapacité en tant qu’auteurs, plutôt que de les encourager à une prolixité accrue. Vers le milieu du Ve siècle en revanche, la production littéraire tendit à se concentrer sur la cour, et l’un des traits particuliers de la littérature des dynasties du Sud est de voir empereurs et princes se joindre à leurs courtisans pour composer des poèmes lors de réunions amicales. Le présent article se concentre sur un certain nombre de poèmes de Song Wendi (r. 424-453), Yan Yanzhi (384-456), Xie Tiao (464-499), Shen Yue (441-513) et Liu Xiaochuo (481-539) qui sont autant de représentations de la royauté et de l’empire, et de ce fait ont servi à propager et réaliser le pouvoir impérial. Est en particulier examinée la construction physique et discursive de la capitale, Jiankang. Tout cela montre le rôle-clé joué par la poésie de cour sous les dynasties du Sud dans l’exercice de la souveraineté et la vision d’un nouvel empire méridional.

Style APA, Harvard, Vancouver, ISO itp.

5

Li, Qing-Jie, Xue-Liang Fang, Ying-Qin Li, Jia-Yi Lin, Cheng-Long Huang, Shi-Wei He, Sheng-Yan Huang i in. "Abstract 1999: DCAF7 acts as a scaffold to recruit USP10 for G3BP1 deubiquitylation and facilitates chemoresistance and metastasis in nasopharyngeal carcinoma". Cancer Research 84, nr 6_Supplement (22.03.2024): 1999. http://dx.doi.org/10.1158/1538-7445.am2024-1999.

Pełny tekst źródła

Streszczenie:

Abstract Though docetaxel plus cisplatin and 5-fluorouracil (TPF) induction chemotherapy becomes the standard care for locoregionally advanced nasopharyngeal carcinoma (NPC), some patients could not benefit from this therapy. The underlying mechanisms remain unclear. We found that DCAF7 was highly expressed in TPF resistant NPC patients, and promoted the cisplatin resistance and metastasis of NPC cells. Mechanistically, DCAF7 facilitates the interaction between USP10 and G3BP1, resulting in the removal of K48-linked ubiquitylation of G3BP1 at Lys76 mediated by USP10, thus preventing the degradation of G3BP1 through ubiquitin-proteasome pathway, and facilitates the stress granule (SG)-like structures formation. Moreover, knockdown of G3BP1 successfully reversed the SG-like structures formation and oncogenic effects exerted by DCAF7. Importantly, NPC patients with elevated DCAF7 expression exhibited high risks of metastasis, and is associated with a poor prognosis. This study identifies DCAF7 as a pivotal cisplatin resistance gene, and sheds light on the underlying mechanism of TPF resistance in NPC patients. The DCAF7-USP10-G3BP1 axis provides potential therapeutic targets and biomarker for NPC treatment. Citation Format: Qing-Jie Li, Xue-Liang Fang, Ying-Qin Li, Jia-Yi Lin, Cheng-Long Huang, Shi-Wei He, Sheng-Yan Huang, Jun-Yan Li, Sha Gong, Kai-Lin Chen, Na Liu, Jun Ma, Yin Zhao, Ling-Long Tang. DCAF7 acts as a scaffold to recruit USP10 for G3BP1 deubiquitylation and facilitates chemoresistance and metastasis in nasopharyngeal carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1999.

Style APA, Harvard, Vancouver, ISO itp.

6

Xigui, Qiu. "Explaining the Character “jin 銫” in Zi Gao 子羔: with a Discussion Concerning Shang Obtaining the Virtue of Metal". Bamboo and Silk 3, nr 1 (7.12.2019): 38–53. http://dx.doi.org/10.1163/24689246-00301002.

Pełny tekst źródła

Streszczenie:

This paper proposes that the character in the sentence 生乃呼曰 “was born and called out: ‘Jin!’” in the Shanghai Museum manuscript Zi Gao 子羔 should be transcribed as 銫, pronounced jin, and was a special way of writing the word jin 金 “metal.” The myth of Xie in Zi Gao may be related to the virtue of Metal of the Shang dynasty, which can still be seen in a story in the Shiyi ji 拾遺記 in which the divine mother asks Jian Di 簡狄 to give birth to Xie to “succeed the Virtue of Metal.” This paper also traces the myths of Shaohao 少皞 and Xie in order to show that Shaohao and Xie derive from the same mythical source. This paper argues that the association of Shang with the virtue of Metal already existed prior to the time that Zou Yan 鄒衍 systematized the Five Virtues.

Style APA, Harvard, Vancouver, ISO itp.

7

Lijing, Wu. "Review of YAN FU AND KE XUE (SCIENCE), by SHEN Guowei. Nanjing: Phoenix Publishing House, 2017". Journal of Cultural Interaction in East Asia 9, nr 1 (1.05.2018): 109–12. http://dx.doi.org/10.1515/jciea-2018-090108.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

Chow, Hei Ching, Tsz Him So, Horace Cheuk Wai Choi i Ka On Lam. "Literature Review of Traditional Chinese Medicine Herbs–Induced Liver Injury From an Oncological Perspective With RUCAM". Integrative Cancer Therapies 18 (styczeń 2019): 153473541986947. http://dx.doi.org/10.1177/1534735419869479.

Pełny tekst źródła

Streszczenie:

Traditional Chinese medicine (TCM) herbs are commonly regarded to be safe with minimal toxicities in Chinese communities. Cancer patients who are receiving Western oncology therapy often concurrently take TCM herbs for anticancer and symptom relief purposes. We performed a literature review for current evidence on TCM herb–induced liver injury from an oncological perspective. A literature search on PubMed was performed to identify publications regarding TCM herbs and concoctions with hepatoprotective or hepatotoxic properties. Lists of commonly used herbs and their causality levels were compiled. In view of the wide range of evidence available, cases assessed by the well-established RUCAM (Roussel Uclaf Causality Assessment Method) algorithm were categorized as the highest level of evidence. More than one case of TCM herb–induced liver injury was confirmed by RUCAM in the following herbs and concoctions: Lu Cha ( Camellia sinensis), Bai Xian Pi ( Dictamnus dasycarpus), Tu San Qi ( Gynura segetum), Jin Bu Huan ( Lycopodium serratum), He Shou Wu ( Polygoni multiflora), Ge Gen ( Pueraria lobata), Dan Lu Tong Du tablet, Shou Wu Pian, Xiao Chai Hu Tang, Xiao Yin pill, and Yang Xue Sheng Fa capsule. Finally, TCM with anticancer or symptom relief uses were discussed in detail with regard to their hepatotoxic or hepatoprotective properties.

Style APA, Harvard, Vancouver, ISO itp.

9

ZHANG, DA-PENG, LI DAI i ZHAN YIN. "A new species of the genus Mongolotettix Rehn, 1928 from Jiangxi, China (Acrididae, Acridoidea, Orthoptera)". Zootaxa 5351, nr 3 (27.09.2023): 397–400. http://dx.doi.org/10.11646/zootaxa.5351.3.9.

Pełny tekst źródła

Streszczenie:

The grasshopper genus Mongolotettix Rehn, 1928 obtains 17 species distributed from the Far Eastern Asian countries, including China, Japan, Korea, Mongolia, and Russia [Bolívar, 1898; Uvarov, 1914; Caudell, 1921; Chogsomzhav, 1974; Li et Lian, 1994; Wan, Ren et Zhang, 1998; Xie et Li, 2000; Kim et Kim 2005; Shi et al, 2016; Shi et al, 2017; Yin et al, 2017; Zheng et al, 2017; Chen et al, 2018; Zhang et al, 2020; Cigliano et al, 2022, Shen et al, 2022]. In the present paper, we describe a new species of the genus from Jiangxi, China. Type specimens are deposited in the Shanghai Entomological Museum, Chinese Academy of Sciences, Shanghai, 200032, China.

Style APA, Harvard, Vancouver, ISO itp.

10

Wang, Honglei, Tai-Shung Chung, Yen Wah Tong, Wenyuan Xie i Fang He. "Reply from Honglei Wang, Tai-Shung Chung, Yen Wah Tong, Wenyuan Xie and Fang He". General physiology and biophysics 32, nr 04 (2013): 595–96. http://dx.doi.org/10.4149/gpb_2013068.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

11

Hung, I.-Ling, Yu-Chiang Hung, Lin-Yi Wang, Sheng-Feng Hsu, Hsuan-Ju Chen, Ying-Jung Tseng, Chun-En Kuo, Wen-Long Hu i Tsai-Chung Li. "Chinese Herbal Products for Ischemic Stroke". American Journal of Chinese Medicine 43, nr 07 (styczeń 2015): 1365–79. http://dx.doi.org/10.1142/s0192415x15500779.

Pełny tekst źródła

Streszczenie:

Traditional Chinese herbal products (CHPs) have been described in ancient medicine systems as treatments for various stroke-associated ailments. This study is aimed to investigate the prescription patterns and combinations of CHPs for ischemic stroke in Taiwan. Prescriptions of CHPs for ischemic stroke were obtained from the National Health Insurance Research Database (NHIRD) of Taiwan. Every prescription with a leading diagnosis of ischemic stroke made during 2000–2010 was analyzed. Descriptive statistics were applied to the pattern of co-prescriptions. Multiple logistic regression models were used to assess demographic and risk factors that are correlated with CHP use. The dataset of inpatient claims data contained information on 15,896 subjects who experienced ischemic stroke from 2000 to 2010. There was an average of 5.82 CHPs in a single prescription for subjects with ischemic stroke. Bu-yang-huan-wu-tang (BYHWT) (40.32%) was by far the most frequently prescribed formula CHP for ischemic stroke, and the most commonly used combination of two-formula-CHP was BYHWT with Shu-jin-huo-xue-tang (SJHXT) (4.40%). Dan Shen (16.50%) was the most commonly used single CHP for ischemic stroke, and the most commonly used combination of two single CHPs was Shi Chang Pua with Yuan Zhi (4.79%). We found that BYHWT and Dan Shen were the most frequently prescribed formula and single CHP for ischemic stroke, respectively. These results provide information about individualized therapy and may contribute to further pharmacologic experiments and clinical trials.

Style APA, Harvard, Vancouver, ISO itp.

12

Gao, Yue, Chun-Jie Liu, Hua-Yi Li, Xiao-Ming Xiong, Sjors G. j. g. In ‘t Veld, Gui-Ling Li, Jia-Hao Liu i in. "Abstract LB168: Platelet RNA signature enables early and accurate detection of ovarian cancer: An intercontinental, biomarker identification study". Cancer Research 82, nr 12_Supplement (15.06.2022): LB168. http://dx.doi.org/10.1158/1538-7445.am2022-lb168.

Pełny tekst źródła

Streszczenie:

Abstract Background: Morpho-physiological alternations of platelets provided a rationale to harness RNA sequencing of tumor-educated platelets (TEPs) for preoperative diagnosis of cancer. Timely, accurate, and non-invasive detection of ovarian cancer in women with adnexal masses presents a significant clinical challenge. Patients and Methods: This intercontinental, hospital-based, diagnostic study included 761 treatment-naïve inpatients with histologically confirmed adnexal masses and 167 healthy controls from nine medical centers (China, n=3; Netherlands, n=5; Poland, n=1) between September 2016 and May 2019. The main outcomes were the performance of TEPs and their combination with CA125 in two Chinese (VC1 and VC2) and the European (VC3) validation cohorts collectively and independently. Exploratory outcome was the value of TEPs in public pan-cancer platelet transcriptome datasets. Results: The AUCs for TEPs in the combined validation cohort, VC1, VC2, and VC3 were 0.918 (95% CI 0.889-0.948), 0.923 (0.855-0.990), 0.918 (0.872-0.963), and 0.887 (0.813-0.960), respectively. Combination of TEPs and CA125 demonstrated an AUC of 0.922 (0.889-0.955) in the combined validation cohort; 0.955 (0.912-0.997) in VC1; 0.939 (0.901-0.977) in VC2; 0.917 (0.824-1.000) in VC3. For subgroup analysis, TEPs exhibited an AUC of 0.858, 0.859, and 0.920 to detect early-stage, borderline, non-epithelial diseases and 0.899 to discriminate ovarian cancer from endometriosis. Analysis of public datasets suggested that TEPs had potential to detect multiple malignancies (Table 1). Conclusions: TEPs had robustness, compatibility, and universality for preoperative diagnosis of ovarian cancer since it withstood validations in populations of different ethnicities, heterogeneous histological subtypes, early-stage ovarian cancer as well as other malignancies. However, these observations warrant prospective validations in a larger population before clinical utilities. Table 1. Performance for TEPs in public pan-cancer datasets. Disease n Healthy Control AUC, area under the curve (95% CI) Women NSCLC (non-small-cell lung cancer) 126 77 0.758 (0.691-0.825) Breast cancer 38 77 0.817 (0.726-0.909) Colorectal cancer 18 77 0.973 (0.945-1.000) Pancreatic cancer 16 77 0.993 (0.981-1.000) Glioblastoma 10 77 0.923 (0.831-1.000) Men NSCLC 119 82 0.746 (0.677-0.815) Colorectal cancer 25 82 0.933 (0.884-0.982) Pancreatic cancer 22 82 0.993 (0.984-1.000) Glioblastoma 19 82 0.981 (0.959-1.000) All NSCLC 245 159 0.774 (0.728-0.820) Colorectal cancer 40 159 0.978 (0.961-0.996) Breast cancer 38 159 0.821 (0.736-0.906) Pancreatic cancer 35 159 0.987 (0.974-0.999) Glioblastoma 35 159 0.931 (0.890-0.972) Hepatobiliary carcinomas 14 159 0.991 (0.978-1.000) Citation Format: Yue Gao, Chun-Jie Liu, Hua-Yi Li, Xiao-Ming Xiong, Sjors G.j.g. In ‘t Veld, Gui-Ling Li, Jia-Hao Liu, Guang-Yao Cai, Gui-Yan Xie, Shao-Qing Zeng, Yuan Wu, Jian-Hua Chi, Qiong Zhang, Xiao-Fei Jiao, Lin-Li Shi, Wan-Rong Lu, Wei-Guo Lv, Xing-Sheng Yang, Jurgen M.j. Piek, Cornelis D de Kroon, C.a.r. Lok, Anna Supernat, Sylwia Łapińska-Szumczyk, Anna Łojkowska, Anna J. Żaczek, Jacek Jassem, Bakhos A. Tannous, Nik Sol, Edward Post, Myron G. Best, Bei-Hua Kong, Xing Xie, Ding Ma, Thomas Wurdinger, An-Yuan Guo, Qing-Lei Gao. Platelet RNA signature enables early and accurate detection of ovarian cancer: An intercontinental, biomarker identification study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB168.

Style APA, Harvard, Vancouver, ISO itp.

13

PARK, JAE-HEE. "Review of “Si Wu Xie(思無邪)” and “Zheng Sheng Yin(鄭聲淫)” in『Analects of Confucius』". Journal of Human Studies 63 (28.02.2024): 37–65. http://dx.doi.org/10.33638/jhs.63.2.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

14

Zheng, Zijian. "(Invited) Textile Composite Electrodes for Wearable Batteries and Beyond". ECS Meeting Abstracts MA2022-02, nr 5 (9.10.2022): 572. http://dx.doi.org/10.1149/ma2022-025572mtgabs.

Pełny tekst źródła

Streszczenie:

Abstract Wearable energy storage devices are indispensable corner stones for future wearable electronics. Current energy storage technologies are based on materials and devices that are rigid, bulky, and heavy, making them difficult to wear. On the other hand, fibers are flexible and lightweight materials that can be assembled into different textiles and have been worn by human beings thousands of years. Different from conventional two-dimensional thin films and foils, the three-dimensional fibre and textile structures not only provide superior wearing ability, but also much larger surface areas. This talk will introduce how our research group makes use of the attributes of fibres for high-performance wearable energy storage devices. We will demonstrate the strategies and discuss the perspectives to modify fibers and textiles for making wearable capacitators and batteries with excellent mechanical durability, electrochemical stability, and high energy/power density. We will also show that the fibrous materials can significantly enhance the stability and energy density of battery for wearable applications and others such as Na battery. References [1] Q. Huang, D. Wang, Z. J. Zheng*, Adv. Energy Mater. 2016, 6, 1600783. [2] Y. Gao, C. Xie, Z. J. Zheng*, Adv. Energy Mater. 2020, 2002838 [3] L. Liu, Y. Yu, C. Yan, K. Li, Z. J. Zheng*, Nat. Commun. 2015, 6, 7260. [4] Y. Yu, C. Yan, Z. J. Zheng*, Adv. Mater. 2014, 26, 55085516. [5] Y. Yang, Q. Huang, L. Niu, D. Wang, C. Yan, Y. She, Z. J. Zheng*, Adv. Mater. 2017, 160667. [6] J. Chang, Z.J.Zheng* et al., Nat. Commun. 2018, 2018, 9, 4480. [7] J. Chang, Q. Huang, and Z. J. Zheng*, Joule 2020, 4, 7, 1346 [8] J. Chang, Q. Huang, Y. Gao, Z. J. Zheng*, Adv. Mater. 2021, 202004419. [9] Y. Gao, H. Hu, J. Chang, Q. Huang, Q. Zhuang, P. Li, Z. J. Zheng*, Adv. Energy Mater. 2021, 2101809. [10] L. Wang, J. Shang, Q. Huang, H. Hu, Y. Zhang, C. Xie, Y. Luo, Y. Gao, H. Wang, Z. J. Zheng*, Adv. Mater. 2021, 2102802.

Style APA, Harvard, Vancouver, ISO itp.

15

Zheng, Zijian. "(Invited) Textile Composite Electrodes for Wearable Batteries and Beyond". ECS Meeting Abstracts MA2023-01, nr 38 (28.08.2023): 2235. http://dx.doi.org/10.1149/ma2023-01382235mtgabs.

Pełny tekst źródła

Streszczenie:

Wearable energy storage devices are indispensable corner stones for future wearable electronics. Current energy storage technologies are based on materials and devices that are rigid, bulky, and heavy, making them difficult to wear. On the other hand, fibers are flexible and lightweight materials that can be assembled into different textiles and have been worn by human beings thousands of years. Different from conventional two-dimensional thin films and foils, the three-dimensional fibre and textile structures not only provide superior wearing ability, but also much larger surface areas. This talk will introduce how our research group makes use of the attributes of fibres for high-performance wearable energy storage devices. We will demonstrate the strategies and discuss the perspectives to modify fibers and textiles for making wearable capacitators and batteries with excellent mechanical durability, electrochemical stability, and high energy/power density. We will also show that the fibrous materials can significantly enhance the stability and energy density of battery for wearable applications and others such as Na battery. References [1] Q. Huang, D. Wang, Z. J. Zheng*, Adv. Energy Mater. 2016, 6, 1600783. [2] Y. Gao, C. Xie, Z. J. Zheng*, Adv. Energy Mater. 2020, 2002838 [3] L. Liu, Y. Yu, C. Yan, K. Li, Z. J. Zheng*, Nat. Commun. 2015, 6, 7260. [4] Y. Yu, C. Yan, Z. J. Zheng*, Adv. Mater. 2014, 26, 55085516. [5] Y. Yang, Q. Huang, L. Niu, D. Wang, C. Yan, Y. She, Z. J. Zheng*, Adv. Mater. 2017, 160667. [6] J. Chang, Z.J.Zheng* et al., Nat. Commun. 2018, 2018, 9, 4480. [7] J. Chang, Q. Huang, and Z. J. Zheng*, Joule 2020, 4, 7, 1346 [8] J. Chang, Q. Huang, Y. Gao, Z. J. Zheng*, Adv. Mater. 2021, 202004419. [9] Y. Gao, H. Hu, J. Chang, Q. Huang, Q. Zhuang, P. Li, Z. J. Zheng*, Adv. Energy Mater. 2021, 2101809. [10] L. Wang, J. Shang, Q. Huang, H. Hu, Y. Zhang, C. Xie, Y. Luo, Y. Gao, H. Wang, Z. J. Zheng*, Adv. Mater. 2021, 2102802.

Style APA, Harvard, Vancouver, ISO itp.

16

Wang, Xu, i Peter Schiavone. "Comment: “Thermal mechanical coupling analysis of two-dimensional decagonal quasicrystals with elastic elliptical inclusion” (Yuan-Yuan Ma, Xue-Fen Zhao, Ting Zhai, Sheng-Hu Ding. Mathematics and Mechanics of Solids (Online First) First Published Online: August 16 2021)". Mathematics and Mechanics of Solids 26, nr 11 (listopad 2021): 1732–34. http://dx.doi.org/10.1177/10812865211054337.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

17

Qing, Min, Xuejun Chen, Wenqing Su, Xiaofang Zhuo, Ting Shen, Chengjuan Xiong, Xuesong Lyu i in. "Abstract 1035: Identification of fibroblast growth factor receptors (FGFRs) alterations (alts) at DNA and RNA-level by one-step next-generation sequencing (NGS) panel". Cancer Research 84, nr 6_Supplement (22.03.2024): 1035. http://dx.doi.org/10.1158/1538-7445.am2024-1035.

Pełny tekst źródła

Streszczenie:

Abstract Background: FGFR inhibitors are currently in clinical development or approved for urothelial cancer and cholangiocarcinoma with FGFR fusion (FUS) or/and mutation (MUT). AmoyDx FGFR 1-4 NGS Panel (FGFR-P) was developed for FGFR alts detection based on both DNA and RNA. The goal of this study is to validate and assess the performance of FGFR-P in pan-cancer FGFR alts detection by comparing with an AmoyDx comprehensive genomic profiling test (CGP) and a health authority approved DNA-based NGS panel (DNA-P). Methods: Both FGFR-P and CGP are DNA (MUT) and RNA (FUS) based for detecting FGFR alts with optimized bioinformatics pipeline to eliminate baseline noise caused by deamination events, which is commonly found in aged FFPE samples. Cell lines, cell line/patient derived xenografts (CDXs/PDXs) and 397 samples of 26 cancer types (90 samples >10 years) were used for validation of FGFR-P. Total 382 and 50 pan-cancer samples were respectively tested to compare FGFR-P with CGP and DNA-P. Results: To validate accuracy, 36 FFPE samples from cell lines and CDXs/PDXs with known FGFR status (25 FUSs, 5 MUTs, 6 wild-types) were tested by FGFR-P with concordance rate 100%. In clinical sample testing, FGFR-P also showed high agreement with CGP (99.5%) and DNA-P (98.0%). Conflicting result confirmed by FISH revealed 1 FUS missed by DNA-P but detected by FGFR-P, which demonstrated advantage of FGFR alts detection by DNA+RNA. In addition, an optimized bioinformatics pipeline by mimic samples with deamination events effectively filtered out C:G>T:A false positive signals. FGFR-P achieved high success rate in testing pan-tumor samples (89.9%) including samples >10 years (75.6%). Conclusions: FGFR-P provides a novel opportunity to identify FGFR alt pan-cancer patients using a robust DNA+RNA NGS platform, which shows high success rate even in aged samples and will be a potent tool for sensitive and reliable detection of FGFR alts for clinical diagnostics. CGP FGFR-P MUT Positive Negative Total Positive 29 0 29 Negative 1 194 195 Total 30 194 224 FUS Positive Negative Total Positive 20 1 21 Negative 0 137 137 Total 20 138 158 The overall percent agreement 99.5% Citation Format: Min Qing, Xuejun Chen, Wenqing Su, Xiaofang Zhuo, Ting Shen, Chengjuan Xiong, Xuesong Lyu, Renee Tate, Qibiao Wu, Longen Zhou, Shibu Thomas, Wangwang Ning, Jianqing Wang, Huihui Yan, Zhiqiang Yin, Zhan Huang, Yaxin Xue, Changbin Zhu. Identification of fibroblast growth factor receptors (FGFRs) alterations (alts) at DNA and RNA-level by one-step next-generation sequencing (NGS) panel [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1035.

Style APA, Harvard, Vancouver, ISO itp.

18

Tariq, Muhammad Usama, Julia Shen, Jaeyong Jung, Namratha Sheshadri, Junrong Yan, Rongrong Li, Kevin Lu i in. "Abstract PO-019: Ubiquitin E3 ligase OSTM1 regulates the cAMP/PKA/CREB pathway and suppresses B-cell malignancies". Blood Cancer Discovery 5, nr 3_Supplement (19.06.2024): PO—019—PO—019. http://dx.doi.org/10.1158/2643-3249.lymphoma24-po-019.

Pełny tekst źródła

Streszczenie:

Abstract B-cell malignancies (BCM) often arise from genomic alterations introduced during different stages of B-cell development. Here, we performed a whole genome targeting CRISPR/Cas9 screen in the immortalized yet non-transformed IL-3-dependent Ba/F3 murine pro-B cell line to identify genes whose loss confers IL-3 independence, reasoning that these genes may function as tumor suppressor genes (TSGs) in BCM. One of the candidate genes is osteoporosis-associated transmembrane protein 1 (OSTM1), an E3 ubiquitin ligase whose loss-of-function causes autosomal recessive osteoporosis. Informatics analysis of patient data showed that OSTM1 is frequently deleted across BCM, which co-occurs with the deletion of a well-characterized TSG Cdkn2a. Genetic silencing of OSTM1 in Ba/F3 cells conferred IL-3-independent survival and proliferation, as well as splenomegaly, lymphadenopathy, and abnormal peripheral blood cell count, indicative of transformation in vivo. Using mass spectrometry screens, we identified phosphodiesterase 3B (PDE3B) as an interacting partner of OSTM1. OSTM1 ubiquitylates PDE3B and promotes its proteasomal degradation. The OSTM1-PDE3B interaction and PDE3B degradation are negatively regulated by OSTM1 N-glycosylation. As PDE3B catalyzes the conversion of cAMP to AMP, it negatively regulates the cAMP-dependent PKA/CREB/CREBBP tumor suppressive pathway. Indeed, overexpression of PDE3B accelerated cell proliferation while PDE3B silencing in OSTM1 KO cells reversed the transformation phenotype in cell lines and in mouse allograft tumors. Importantly, a strong correlation between OSTM1 disruption, increased PDE3B stability, and decreased PKA/CREB/CEBBP signaling was observed in cell lines and in BCM patient datasets. Finally, CD19-Cre mediated B-cell specific ablation of OSTM1 cooperated with CDKN2A deletion to drive spontaneous immature B-cell lymphomagenesis in mice. Collectively, these results indicate that OSTM1 is a novel TSG which targets PDE3B for proteasomal degradation. Loss of OSTM1 enhances PDE3B stability and abrogates the tumor-suppressive role of cAMP/CREB/CREBBP pathway which promotes BCM. Citation Format: Muhammad Usama Tariq, Julia Shen, Jaeyong Jung, Namratha Sheshadri, Junrong Yan, Rongrong Li, Kevin Lu, Tong Liu, Hong Li, Yue Lynn Wang, Ping Xie, Wei-Xing Zong. Ubiquitin E3 ligase OSTM1 regulates the cAMP/PKA/CREB pathway and suppresses B-cell malignancies [abstract]. In: Proceedings of the Fourth AACR International Meeting on Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application; 2024 Jun 19-22; Philadelphia, PA. Philadelphia (PA): AACR; Blood Cancer Discov 2024;5(3_Suppl):Abstract nr PO-019.

Style APA, Harvard, Vancouver, ISO itp.

19

Laveine, Jean-Pierre, Shanzhen Zhang i Yves Lemoigne. "The paleogeographic distribution of the parispermaceae: An answer to the papers by Li Xing-Xue, Shen Guang-long and Wu Xiu-Yuan, entitled: “First appearange of paripterids and their migration and dispersion” and by Wu Xiu-Yuan and shen Guang-long, entitled: “Preliminary study of the migration and dispersion of neuropterids”". Geobios 27, nr 4 (styczeń 1994): 395–401. http://dx.doi.org/10.1016/s0016-6995(09)90017-1.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

20

Lu, Shun, Meili Sun, Yunpeng Liu, Yanping Hu, Yanyan Xie, Zhehai Wang, Dong Wang i in. "Abstract LB512: RATIONALE-304: The association of tumor mutational burden (TMB) with clinical outcomes of tislelizumab (TIS) + chemotherapy (chemo) versus chemo alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC)". Cancer Research 82, nr 12_Supplement (15.06.2022): LB512. http://dx.doi.org/10.1158/1538-7445.am2022-lb512.

Pełny tekst źródła

Streszczenie:

Abstract Background: In the primary analysis of RATIONALE-304 (NCT03663205), TIS + platinum-based chemo significantly improved clinical outcomes over chemo alone in treatment-naïve advanced nsq-NSCLC (median progression-free survival [PFS] by IRC [9.7 vs 7.6 months, HR=0.645, p=0.0044]). Here we report biomarker analysis of baseline tissue and blood TMB (tTMB and bTMB, respectively). Methods: Patients with nsq-NSCLC were randomized 2:1 to TIS + platinum + pemetrexed or platinum + pemetrexed. TMB scores were evaluated on baseline tumor and blood samples by OncoScreen Plus®. The Spearman’s rank correlation of tTMB with bTMB was assessed. PFS by independent review committee (primary endpoint) was assessed within subgroups defined by TMB status, using a Cox proportional hazard model with disease stage and programmed death-ligand 1 (PD-L1) expression as stratification factors. Interaction p-values < 0.05 were considered statistically significant without multiplicity adjustment. Results: Of 325 patients treated in RATIONALE-304, without an EGFR sensitizing mutation, 177 (54.5%) had evaluable tTMB and 107 (32.9%) had evaluable bTMB. Median tTMB and bTMB were 7.2 and 3.1 mut/Mb, respectively. There was a modest correlation between tTMB and bTMB (r=0.71, p < 0.001). Prolonged PFS benefit of adding TIS to chemo was oberved in patients with TMB-high status compared with TMB-low status (Table). Interaction analysis showed that neither tTMB nor bTMB significantly differentiated treatment-specific PFS benefit (interaction p-values > 0.05; Table). Conclusions: In this retrospective analysis, neither tTMB nor bTMB was significantly associated with PFS benefit, suggesting limited clinical utility of tTMB and bTMB in the setting of TIS + chemo as first-line therapy for advanced nsq-NSCLC. Association of TMB with PFS benefit of TIS + chemo vs chemo tTMB bTMB Cutoffs mut/Mb N HR (95% CI) Interaction Cutoffs mut/Mb N HR (95% CI) Interaction p-value p-value BEP 177 0.76 (0.46, 1.25) NA BEP 107 0.48 (0.26, 0.87) NA ≥ 8 (TMB-high) 80 0.52 (0.25, 1.10) 0.208 ≥ 4 (TMB-high) 47 0.30 (0.12, 0.75) 0.212 < 8 (TMB-low) 97 0.98 (0.51, 1.88) < 4 (TMB-low) 60 0.64 (0.29, 1.39) BEP, biomarker evaluable population; bTMB, blood tumor mutational burden; CI, confidence interval; HR, hazard ratio; Mb, megabase; mut, mutation; NA, not applicable; PFS, progression-free survival; TIS, tislelizumab; TMB, tumor mutational burden; tTMB, tissue tumor mutational burden Citation Format: Shun Lu, Meili Sun, Yunpeng Liu, Yanping Hu, Yanyan Xie, Zhehai Wang, Dong Wang, Zhenzhou Yang, Liang Liang, Yi Huo, Yun Zhang, Ruiqi Huang, Yang Shi, Zhirong Shen, Yan Yu. RATIONALE-304: The association of tumor mutational burden (TMB) with clinical outcomes of tislelizumab (TIS) + chemotherapy (chemo) versus chemo alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB512.

Style APA, Harvard, Vancouver, ISO itp.

21

Yang, Zheng, Wuzhong Shen, Guiyun Tu, Shenjie Xue, Ying Tan, Bingbin Xie, Jason Xu, Hanyang Chen, Shui Liu i Xiaoqiang Yan. "Abstract 6704: Development and characterization of a tri-specific selective CD8 T cell engager (CD8xCD3xCD19) for treatment of B cell lymphoma". Cancer Research 84, nr 6_Supplement (22.03.2024): 6704. http://dx.doi.org/10.1158/1538-7445.am2024-6704.

Pełny tekst źródła

Streszczenie:

Abstract The recent development of CD3 bi-specific antibodies (BsAbs) targeting CD20, BCMA, GPRC5D and CD19 to treat B cell malignancies have resulted in significant clinical benefit to patients. However, long-term remission rates and survival remain to be demonstrated. Current CD3 BsAbs preferentially bind to and activate CD4 T cells. However, CD8 cytotoxic T cells also play the key role in anti-tumor response and T cell exhaustion in cancer immunity. To potentially enhance anti-tumor efficacy by augmenting CD8 T-cell response, we developed a novel tri-specific T cell engager (TriTE) IM-8319, which simultaneously binds human CD3, CD8 and CD19 epitopes with KD at 14.2 nM, 3.3 nM and 0.3 nM, respectively. The binding affinity to human CD8 T cells and CD4 T cells was measured with EC50 at 0.02 nM and 1.2 nM, respectively. In human PBMC-killing assays, IM-8319 was found to preferentially activate CD8 T cells with EC50 of 6.0 pM, compared to an EC50 of 94 pM for activating CD4 T cells. Unique cytokine release responses were seen with IM-8319 treatment. Compared to bi-specific TCE controls without CD8 binding domain, IM-8319 in human PBMC assays increased INFγ and TNFα in CD8 T cells and blunted IL-2 release in CD4 T cells. We observed robust cytotoxic killing of CD19+ B cells with IM-8319. Compared the bi-specific TCE controls lacking CD8 binding domain, in vitro CD19+ B-cell depletion was increased 6-fold with IM-8319. In addition, we observed notable structure activity relationships, with >100-fold increases in TriTE cytotoxicity with a weak CD3 binding domain. T-cell fratricide has hindered the development of antibodies containing 2+ T-cell epitopes. We observed correctable, dose-dependent CD8 T cell depletion at high concentrations of CD8xCD3xCD19 TriTEs in vitro and xenograft mouse models. This unwanted biological effect was not a surprise when the TriTE binds to CD8 T cells in trans. However, by structure engineering IM-8319 to allow for cis binding of CD3 and CD8, we effectively eliminated CD8 T cell fratricide at therapeutic doses. In a Raji-inoculated murine xenograft that was reconstituted with human PBMC, IM-8319 significantly inhibited tumor growth without obvious CD8 T cell depletion. In summary, we report a novel TriTE (IM-8319) that selectively binds to and activates CD8 T cells. IM-8319 results in robust on-target cytotoxicty with specific activation of CD8 T cells, suggesting potential to reduce systemic toxicities such as cytokine release syndrome (CRS) while augmenting direct antitumor efficacy. Further preclinical evaluation of IM-8319 is warranted in patients with B-cell leukemias and lymphomas. Citation Format: Zheng Yang, Wuzhong Shen, Guiyun Tu, Shenjie Xue, Ying Tan, Bingbin Xie, Jason Xu, Hanyang Chen, Shui Liu, Xiaoqiang Yan. Development and characterization of a tri-specific selective CD8 T cell engager (CD8xCD3xCD19) for treatment of B cell lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6704.

Style APA, Harvard, Vancouver, ISO itp.

22

Fan, Fa-ti. "Zonggang Hu. Jingsheng sheng wu diao cha suo shi gao [Historical manuscript of Fan Memorial Institute of Biology]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 250 pp., illus., figs., tables, bibl., index. Jinan: Shangdong jiao yu chu ban she [Shandong Education Press], 2005. 29 yuan (paper)." Isis 99, nr 1 (marzec 2008): 214. http://dx.doi.org/10.1086/589390.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

23

Zhou, Liheng, Shuguang Xu, Xiaohong Xue, Yinzhou Zhang, Bei Gu, Baoxing Lin, Junwen Bai i in. "Abstract P2-12-02: Efficacy, safety and survival of neoadjuvant chemotherapy with different estrogen deprivation stratified by menstrual status versus chemotherapy alone in locally advanced breast cancer (SHPD002)—— A randomized multicentre, open-label, phase 3 Triab". Cancer Research 82, nr 4_Supplement (15.02.2022): P2–12–02—P2–12–02. http://dx.doi.org/10.1158/1538-7445.sabcs21-p2-12-02.

Pełny tekst źródła

Streszczenie:

Abstract BackgroundAchieving pathologic complete response (pCR) because of neoadjuvant therapy has been correlated with long-term clinical benefit, however, luminal-like tumors achieve a lower rate of pCR in comparison with other subtypes. The Shanghai Pudong (SHPD) 002 trial compares neoadjuvant chemotherapy concurrently with or with different estrogen deprivation therapy separately in premenopausal and postmenopausal patients with locally advanced breast cancer. MethodsIn this prospective, multicentre, neoadjuvant, phase III trial, 236 patients with locally advanced breast cancer were randomly assigned (2:1) to receive neoadjuvant chemotherapy (NCT) with gonadotropin-releasing hormone agonist (GnRHa) in premenopausal women or letrozole in postmenopausal women compared with chemotherapy alone. The primary endpoint was pCR (ypT0/is/ypN0). Secondary endpoints included disease-free survival, overall survival, and safety. This trial is registered with ClinicalTrials.gov, number NCT NCT02221999.Results A total of 236 patients were included. pCR was achieved by 20.4% in the chemotherapy plus ET group and 38.6% in the chemotherapy group. In postmenopausal patients, pCR was observed in 22.6% when treated with letrozole, 32.4% with NCT alone (p=0.276). Premenopausal patients with NCT and GnRHa achieved a significantly lower pCR of 18.8% than those of 42.9% in patients with NCT alone(p=0.003). A posthoc analysis showed CPS+EG score 0-3 was significantly more probable in patients with GnRHa (OR, 0.245; 95% CI, 0.072 to 0.832, P=0.024) than in those without GnRHa in the premenopausal patients who didn’t achieve near-pCR. After a median follow-up of 45 months, there was no significant difference concerning disease-free survival (DFS) (p=0.874) or overall survival (OS) (P =0.947) between the 2 postmenopausal groups. GnRHas significantly improved survival outcome in premenopausal patients (3-year OS, 100% with GnRHas, vs 88.2% without; log-rank p=0.034). Improved DFS (log-rank p = 0.001) and OS (log-rank p=0.003) were strongly associated with pCPS+EG score and GnRHa usage in premenopausal patients.ConclusionsConcurrent administration of GnRHas during neoadjuvant chemotherapy improves OS in premenopausal patients, though it does not increase the pCR rate. The adoption of the CPS+EG score may be a better surrogate endpoint for survival outcomes. The addition of letrozole to neoadjuvant chemotherapy confers no therapeutic advantage in terms of tumor response or survival outcome. Citation Format: Liheng Zhou, Shuguang Xu, Xiaohong Xue, Yinzhou Zhang, Bei Gu, Baoxing Lin, Junwen Bai, Hongwei Zhang, Kejin Wu, Yanping Lin, Yumei Ye, Yueyao Du, Xiaonan Sheng, Yaqian Xu, Jie Zhang, Wenjin Yin, Jinsong Lu. Efficacy, safety and survival of neoadjuvant chemotherapy with different estrogen deprivation stratified by menstrual status versus chemotherapy alone in locally advanced breast cancer (SHPD002)—— A randomized multicentre, open-label, phase 3 Triab [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-12-02.

Style APA, Harvard, Vancouver, ISO itp.

24

Glauber, Jean-Pierre, Ji Liu, Julian Lorenz, Sebastian Bragulla, Björn Müller, Corinna Harms, Michael Wark, Michael Nolan i Anjana Devi. "MOCVD of ZrN: Tuning Thin Film Properties Towards Catalytic Applications". ECS Meeting Abstracts MA2023-02, nr 47 (22.12.2023): 2352. http://dx.doi.org/10.1149/ma2023-02472352mtgabs.

Pełny tekst źródła

Streszczenie:

Transition metal nitrides (TMN) have gained increasing attention over recent years as active materials for energy related applications including catalysis and energy storage. They feature high electrical conductivities, wide optical band gaps and superior chemical stability.[1] In particular, ZrN has been recently identified as a promising material for a range of potential applications that include plasmonic devices,[2] as a catalyst for the oxygen reduction reaction (ORR),[3] and as a catalyst for the nitrogen reduction reaction (NRR),[4] due to its appealing electronic properties, while being cheap and abundant compared to commonly used noble metals.[1,5] The fabrication of ZrN on large scale under moderate process conditions, with the required properties for catalytic applications, motivates the use of chemical vapor deposition (CVD) as the method of choice. Moreover, with the variation of process parameters that includes precursor choice and growth temperature, it is possible to tune the surface features as well as composition of the layers that are suitable for catalytic applications. In this study, we have employed metal organic chemical vapor deposition (MOCVD) to synthesize ZrN layers on Si and glassy carbon (GC) substrates in the temperature range of 550 – 850 °C. The influence of the nature of the precursor and deposition temperature on the structure, composition and surface morphology of the ZrN layers was systematically studied. Oriented ZrN layers with facetted grain morphology were obtained. ZrN films of different thickness were analyzed by complementary methods including X-ray diffraction (XRD) (Figure 1 a)), Raman spectroscopy, Rutherford backscattering spectrometry (RBS) (Figure 1 b)), nuclear reaction analysis (NRA), scanning electron microscopy (SEM) (Figure 1 c)), and X-ray photoelectron spectroscopy (XPS). Based on the detailed film analysis, catalyst surfaces were modeled by DFT calculations. The NRR activity and selectivity towards the competing hydrogen evolution reaction (HER) were evaluated by first principles simulations and electrochemical experiments. This preliminary study on material fabrication and theoretical investigations lays a foundation for the investigation of ZrN for NRR applications for future studies. References: [1]: Luo, Q.; Lu, C.; Liu, L.; Zhu, M., Green Energy & Environ. 2023 8 (2), 406. [2]: Shabani, A.; Tsegay K., M.; Petersen, S.; Khazaei N., M.; Kumar M., Y.; Adam, J., Adv Photo Res. 2021 2 (11), 2100178. [3]: Yuan, Y.; Wang, J.; Adimi, S.; Shen, H.; Thomas, T.; Ma, R. et al., Nat. Mater. 2020, 19 (3), 282. [4]: Abghoui, Y.; Garden, A. L.; Howalt, J. G.; Vegge, T.; Skúlason, E., ACS Catal. 2016 6 (2), S. 635. [5]: Xie, J.; Xie, Y., Chemistry 2016, 22, 3588. Figure 1

Style APA, Harvard, Vancouver, ISO itp.

25

Liu, Zhuqing, Yong Xia, Linlin Li, Yan Sun, Zhicai Lin, Lijie Rong, Zhongzheng Zhu i in. "Abstract CT134: Non-viral mesothelin-targeted CAR-T cells armored with IFNg-induced secretion of PD-1 nanobody in treatment of malignant mesothelioma in phase I clinical trial". Cancer Research 83, nr 8_Supplement (14.04.2023): CT134. http://dx.doi.org/10.1158/1538-7445.am2023-ct134.

Pełny tekst źródła

Streszczenie:

Abstract Background: Malignant pleural/peritoneal mesothelioma (MPM) is a rare, aggressive cancer with poor prognosis and high mortality of 65%-70% for pleural and 30% for peritoneal MPM. Patients who fail the standard therapy often survive less than 1 year, so it is urgent to develop new effective therapies for MPM patients. Chimeric antigen receptor (CAR)-T cells have been applied in MPM, but the efficacy was still limited due to immunosuppressive tumor microenvironment (TME). To overcome these obstacles, we developed armored CAR-T cells with nanobody targeting mesothelin (MSLN) and IFN-γ-activated secretion of PD-1 nanobody in a non-viral transposon system, named as BZDS1901. Preclinical studies have demonstrated cytotoxicity of the BZDS1901 in NCI-H226 lung/mesothelioma xenograft mouse model. To verify the safety and efficacy of BZDS1901, we conducted a single-arm, open label, dose-escalating clinical trials (NCT04503980, 05089266, 03615313) in solid tumors. Methods: Eligible patients were those who failed prior standard therapies with MSLN expression (≥50%) and PD-L1 positive in tumor specimen and voluntarily signed the informed consent. After apheresis and lymphodepletion with cyclophosphamide and fludarabine. BZDS1901 was administered intravenously in dose cohorts (1 × 106-2 × 107/kg) and the second infusion was given if no disease progression. After infusion, safety was evaluated during 28 days by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, efficacy was assessed by RECIST 1.1 or mRECIST with CT scan. Blood CAR copies were measured by qPCR, PD-1 nanobodies and cytokines by Meso Scale Discovery method, and T cell subtypes by flow cytometry. Patients’ progression-free survival (PFS) and overall survival (OS) were measured from the day of infusion to progression or death. Results: From July 20, 2020 to December 31, 2022, 11 MPM patients were enrolled and completed the assessment, while most patients received two infusions. BZDS1901 was safe, demonstrated by 54% grade 3 and 15% grade adverse events (AEs) that were hematological side effects due to lymphodepletion and reversible with supportive care. No on-target, off-tumor toxicity and dose-limiting toxicity were observed. All patients showed expansion of CAR-T cells and increased PD-1 nanobodies in circulation. CAR-T Cmax (cp/μg) copies number was 20062, and continually detectable in blood over 4 months. PD-1 Cmax (pg/ml) was 82841, and continually detectable in blood for up to 9 months. IFN- γ and IL-6 also increased at day 4 or Day 7. All patients obtained objective tumor response, one with complete response, six with partial response, and four with stable disease. The total objective response rate was 63.64%. All enrolled patients are still alive, and mPFS and mOS are not reached. The longest PFS was up to 26 months. Median follow-up was four months. Conclusions: PD-1 nanobody secreted and MSLN targeting CAR-T cells have demonstrated promising efficacy on MPM patients. Besides CAR-T direct tumor killing activity, secreted PD-1 nanobodies may provide additional clinical benefit by invigorating CAR-T from PD-L1 inhibition, activating TILs and relieving local immunosuppression. Citation Format: Zhuqing Liu, Yong Xia, Linlin Li, Yan Sun, Zhicai Lin, Lijie Rong, Zhongzheng Zhu, Zongchang Song, Hui Xue, Jianchun Duan, Shujing Shen, Jing Wang, Linjie Lv, Yaping Yang, Xue Tan, Liping Han, Wei Zhao, Jie Wang, Wenfeng Xu, Weimin Zhu, Zhong Li, Xingya Li, Jinxing Lou, Qing Xu, Qijun Qian. Non-viral mesothelin-targeted CAR-T cells armored with IFNg-induced secretion of PD-1 nanobody in treatment of malignant mesothelioma in phase I clinical trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT134.

Style APA, Harvard, Vancouver, ISO itp.

26

Sheshadri, Namratha, Rongrong Li, Muhammad Usama Tariq, Jianliang Shen, Jaeyong Jung, Junrong Yan, Kevin Lu, Zhiyuan Shen, Ping Xie i Wei-Xing Zong. "Abstract PO-035: Genome-wide CRISPR knockout screen identifies sialylation as a tumor suppressive mechanism in B-cell malignancies". Blood Cancer Discovery 5, nr 3_Supplement (19.06.2024): PO—035—PO—035. http://dx.doi.org/10.1158/2643-3249.lymphoma24-po-035.

Pełny tekst źródła

Streszczenie:

Abstract Ba/F3 is a murine pro-B cell line that is dependent on interleukin-3 (IL-3) for its survival and proliferation. It has been widely used for identifying oncogenes and mechanisms of drug-resistance. Using this cell line, we conducted a genome-wide CRISPR knockout screen to identify genes whose loss can confer IL-3 independence, hence may be implied as tumor suppressor genes (TSGs). We identified several genes that map to human chromosome 6q, a frequent deletion hotspot in B-cell malignancies, that may act as TSGs. One of these putative novel TSGs is Slc35a1, which encodes the membrane solute carrier that facilitates the transport of nucleotide sugar (CMP-sialic acid) into the Golgi apparatus for subsequent sialylation. Interestingly, in addition to Slc35a1, pathway analysis of hits from the CRISPR screen identified several genes in the sialic acid metabolism pathway, Nans, Cmas, and St3gal5. We confirmed that their silencing led to decreased protein sialyation and could confer IL-3-independent cell survival and growth in Ba/F3 cells. We continued to characterize Slc35a1 since its homozygous and heterozygous deletions are seen in 7-40% of different types of B-cell malignancies, including approximately 40% of patients with Diffuse Large B-cell Lymphoma. Slc35a1 deletion in murine and human cell-lines conferred cytokine-independent growth. Tail-vein injection of Slc35a1-silenced Ba/F3 cells resulted in allograft tumor growth presenting with splenomegaly and lymphadenopathy. Using Maackia amurensis lectin II (MAL II) to pull down sialylated proteins for mass spectrometry, we identified proteins that were differentially sialylated in Slc35a1 wild-type and knockout cells, among which are the α and β subunits of the integrin receptor, lymphocyte functional antigen 1 (LFA-1). As integrin desialylation can promote its constitutive activation, we are currently studying the impact of LFA-1 sialylation on B-cell function and transformation. We have also developed mouse models with B-cell specific ablation of Nans and Slc35a1 to further evaluate the role of sialylation on B-cell development and tumorigenesis in vivo. Overall, our study demonstrates that sialylation may function as a tumor suppressive mechanism and serve as a therapeutic target in B-cell cancers. Citation Format: Namratha Sheshadri, Rongrong Li, Muhammad Usama Tariq, Jianliang Shen, Jaeyong Jung, Junrong Yan, Kevin Lu, Zhiyuan Shen, Ping Xie, Wei-Xing Zong. Genome-wide CRISPR knockout screen identifies sialylation as a tumor suppressive mechanism in B-cell malignancies [abstract]. In: Proceedings of the Fourth AACR International Meeting on Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application; 2024 Jun 19-22; Philadelphia, PA. Philadelphia (PA): AACR; Blood Cancer Discov 2024;5(3_Suppl):Abstract nr PO-035.

Style APA, Harvard, Vancouver, ISO itp.

27

Liu, Ziqi, Min Hwan Lee i ThomasJae Garcia. "3D Metal-Organic Framework Based Layered Double Hydroxide Core Shell Structure for Enhanced Oxygen Evolution Reaction". ECS Meeting Abstracts MA2022-02, nr 44 (9.10.2022): 1684. http://dx.doi.org/10.1149/ma2022-02441684mtgabs.

Pełny tekst źródła

Streszczenie:

Electrochemical water splitting, an effective approach of generating high purity hydrogen in a clean way, is composed of two half reactions: hydrogen evolution reaction (HER) and oxygen evolution reaction (OER).[1] OER is the main rate-limiting half reaction for water splitting due to its sluggish four-electron transfer process.[2] , [3] An efficient electrocatalyst is indispensable to minimize the activation barrier for the reaction and achieve a high efficiency. Recently, two-dimensional (2D) layered double hydroxides (LDHs) have shown promises as one of the most effective electrocatalysts towards OER. However, the confined nanostructure with poor electronic conductivity inhibits their further enhanced catalytic performance towards OER. Herein, a 3D core-shell LDH structure is synthesized through a facile one-step reaction strategy, in which the terephthalic acid and urea is employed as the organic ligand for the metal organic framework (MOF) precursor and surface coordination buffer between LDH and MOF. Benefiting from the hierarchical 3D microstructure with uniformly nanosheets grown on the surface, the as prepared electrocatalyst exhibits rich edge active sites and enormous electrochemical surface area. The representative sample (namely, CoNi-LDH@BDC) achieves an excellent OER activity with a low overpotential of 280 mV at 100 mA cm-2 and robust cyclic stability. In addition, quasi-operando studies using X-ray absorption and X-ray photoelectron spectroscopy further elucidate that the Co-Ni dual metal sites act as the main active site while Ni of high valence state is a favorable site to oxygen for the O-O bond formation. The prominent OER performance is also attributed to the synergistic effect between different transition metal atoms. References [1] L. Yu, H. Zhou, J. Sun, F. Qin, F. Yu, J. Bao, Y. Yu, S. Chen, Z. Ren, Energy Environ. Sci. 2017, 10, 1820. [2] Y. Wang, C. Xie, Z. Zhang, D. Liu, R. Chen, S. Wang, Adv. Funct. Mater. 2018, 28, 1703363. [3] L. Zhuang, L. Ge, Y. Yang, M. Li, Y. Jia, X. Yao, Z. Zhu, Adv. Mater. 2017, 29, 1606793. [4] R. Frydendal, E. A. Paoli, B. P. Knudsen, B. Wickman, P. Malacrida, I. E. L. Stephens, I. Chorkendorff, ChemElectroChem 2014, 1, 2075. [5] Y. Lee, J. Suntivich, K. J. May, E. E. Perry, Y. Shao-Horn, Synthesis and activities of rutile IrO 2 and RuO 2 nanoparticles for oxygen evolution in acid and alkaline solutions, Vol. 3, American Chemical Society, 2012, pp. 399–404. [6] M. Gao, W. Sheng, Z. Zhuang, Q. Fang, S. Gu, J. Jiang, Y. Yan, J. Am. Chem. Soc. 2014, 136, 7077.

Style APA, Harvard, Vancouver, ISO itp.

28

., Nagmani, Dhrubajyoti Das i Sreeraj Puravankara. "Boosting the Initial Coulombic Efficiency of Sustainable Hard Carbon Derived from Polyethylene Terephthalate with Cyclopentyl Methyl Ether As a Co-Solvent for Wide-Temperature Sodium-Ion Batteries". ECS Meeting Abstracts MA2023-02, nr 1 (22.12.2023): 123. http://dx.doi.org/10.1149/ma2023-021123mtgabs.

Pełny tekst źródła

Streszczenie:

Upcycling plastic waste into value-added products helps to generate cost-effective and sustainable resources towards a circular materials economy and safer ecosystem. The conversion of polyethylene terephthalate (PET) municipal waste via the carbonization process into hard carbon (HC) delivers a high-reversible capacity, low-cost, sustainable anode material for sodium-ion batteries (SIBs). However, the low initial Coulombic efficiency (ICE) is a significant challenge of the HC anode, which should be optimized by electrolyte and interfacial chemistry.1 In conventional carbonate esters-based electrolytes, ethylene carbonate (EC) forms an organic-rich thick SEI layer, soluble on cycling, limiting the cyclic stability. The low-temperature performance is also a significant concern in achieving high capacity, long cyclability, and ICE.2 Herein, HC derived via single-step carbonization at 1000℃ exhibits larger interlayer spacing of 0.379 nm, low surface area (~205 m2g-1), and unique slit-shaped pores with 84% mesoporosity in the structure. PET-HC exhibits a high reversible capacity of 337 mAh g-1 with ICE of just 66%, using EC-PC-based electrolyte. EC-free cyclopentyl methyl ether (CPME) was used due to its weakly solvating and wide temperature solvent.3 CPME-PC-based electrolytes significantly enhanced the ICE value to 74.5% and reversible capacity to 356 mAh g-1 with superior cycling of 91% after 100 cycles at 0.1C rate. The inorganic-rich SEI layer for CPME-PC-based electrolytes results in a thin SEI that improves the ICE and cyclic stability of the anode. The low-temperature performance (up to -20°C) for CPME-PC-based electrolytes showed ~30% added capacity compared to EC-PC-based electrolytes. This work provided an eco-friendly approach to developing hard carbons from plastic trash and offered an effective strategy to replace EC with CPME for low-temperature sodium storage applications. References Shen, L., Shi, S., Roy, S., Yin, X., Liu, W., Zhao, Y., Adv. Funct. Mater. 2021, 31, 2006066. Ramasamy, H. V., Kim, S., Adams, E. J., Rao, H. & Pol, V. G. Chem. Commun. 2022, 58, 5124–5127. Zhang, H., Zeng, Z., Ma, F., Wu, Q., Wang, X., Cheng, S., Xie, J., Angew. Chem. 2023, e202300771. Figure 1

Style APA, Harvard, Vancouver, ISO itp.

29

Li, Shang‐Jen. "Guihan Luo. Jin dai xi fang shi Hua sheng wu shi [History of Western Botanical and Zoological Studies in China]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 434 pp., illus., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2005. ¥46 (paper)." Isis 99, nr 2 (czerwiec 2008): 380–81. http://dx.doi.org/10.1086/591325.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

30

Fang, Yin-Ying, Chi-Fang Chen i Sheng-Ju Wu. "Feature identification using acoustic signature of Ocean Researcher III (ORIII) of Taiwan". ANZIAM Journal 59 (25.07.2019): C318—C357. http://dx.doi.org/10.21914/anziamj.v59i0.12655.

Pełny tekst źródła

Streszczenie:

Underwater acoustic signature identification has been employed as a technique for detecting underwater vehicles, such as in anti-submarine warfare or harbour security systems. The underwater sound channel, however, has interference due to spatial variations in topography or sea state conditions and temporal variations in water column properties, which cause multipath and scattering in acoustic propagation. Thus, acoustic data quality control can be very challenging. One of challenges for an identification system is how to recognise the same target signature from measurements under different temporal and spatial settings. This paper deals with the above challenges by establishing an identification system composed of feature extraction, classification algorithms, and feature selection with two approaches to recognise the target signature of underwater radiated noise from a research vessel, Ocean Researcher III, with a bottom mounted hydrophone in five cruises in 2016 and 2017. The fundamental frequency and its power spectral density are known as significant features for classification. In feature extraction, we extract the features before deciding which is more significant from the two aforementioned features. The first approach utilises Polynomial Regression (PR) classifiers and feature selection by Taguchi method and analysis of variance under a different combination of factors and levels. The second approach utilises Radial Basis Function Neural Network (RBFNN) selecting the optimised parameters of classifier via genetic algorithm. The real-time classifier of PR model is robust and superior to the RBFNN model in this paper. This suggests that the Automatic Identification System for Vehicles using Acoustic Signature developed here can be carried out by utilising harmonic frequency features extracted from unmasking the frequency bandwidth for ship noises and proves that feature extraction is appropriate for our targets. References Nathan D Merchant, Kurt M Fristrup, Mark P Johnson, Peter L Tyack, Matthew J Witt, Philippe Blondel, and Susan E Parks. Measuring acoustic habitats. Methods in Ecology and Evolution, 6(3):257265, 2015. doi:10.1111/2041-210X.12330. Nathan D Merchant, Philippe Blondel, D Tom Dakin, and John Dorocicz. Averaging underwater noise levels for environmental assessment of shipping. The Journal of the Acoustical Society of America, 132(4):EL343EL349, 2012. doi:10.1121/1.4754429. Chi-Fang Chen, Hsiang-Chih Chan, Ray-I Chang, Tswen-Yung Tang, Sen Jan, Chau-Chang Wang, Ruey-Chang Wei, Yiing-Jang Yang, Lien-Siang Chou, Tzay-Chyn Shin, et al. Data demonstrations on physical oceanography and underwater acoustics from the marine cable hosted observatory (macho). In OCEANS, 2012-Yeosu, pages 16. IEEE, 2012. doi:10.1109/OCEANS-Yeosu.2012.6263639. Sauda Sadaf P Yashaswini, Soumya Halagur, Fazil Khan, and Shanta Rangaswamy. A literature survey on ambient noise analysis for underwater acoustic signals. International Journal of Computer Engineering and Sciences, 1(7):19, 2015. doi:10.26472/ijces.v1i7.37. Shuguang Wang and Xiangyang Zeng. Robust underwater noise targets classification using auditory inspired time-frequency analysis. Applied Acoustics, 78:6876, 2014. doi:10.1016/j.apacoust.2013.11.003. LG Weiss and TL Dixon. Wavelet-based denoising of underwater acoustic signals. The Journal of the Acoustical Society of America, 101(1):377383, 1997. doi:10.1121/1.417983. Timothy Alexis Bodisco, Jason D'Netto, Neil Kelson, Jasmine Banks, Ross Hayward, and Tony Parker. Characterising an ecg signal using statistical modelling: a feasibility study. ANZIAM Journal, 55:3246, 2014. doi:10.21914/anziamj.v55i0.7818. José Ribeiro-Fonseca and Luís Correia. Identification of underwater acoustic noise. In OCEANS'94.'Oceans Engineering for Today's Technology and Tomorrow's Preservation.'Proceedings, volume 2, pages II/597II/602 vol. 2. IEEE. Linus YS Chiu and Hwei-Ruy Chen. Estimation and reduction of effects of sea surface reflection on underwater vertical channel. In Underwater Technology Symposium (UT), 2013 IEEE International, pages 18. IEEE, 2013. doi:10.1109/UT.2013.6519874. G.M. Wenz. Acoustic ambient noise in the ocean: spectra and sources. Thesis, 1962. doi:10.1121/1.1909155. Donald Ross. Mechanics of underwater noise. Elsevier, 2013. doi:10.1121/1.398685. Chris Drummond and Robert C Holte. Exploiting the cost (in) sensitivity of decision tree splitting criteria. In ICML, volume 1, 2000. Charles Elkan. The foundations of cost-sensitive learning. In International joint conference on artificial intelligence, volume 17, pages 973978. Lawrence Erlbaum Associates Ltd, 2001. Chris Gillard, Alexei Kouzoubov, Simon Lourey, Alice von Trojan, Binh Nguyen, Shane Wood, and Jimmy Wang. Automatic classification of active sonar echoes for improved target identification. Douglas C Montgomery. Design and analysis of experiments. John wiley and sons, 2017. doi:10.1002/9781118147634. G Taguchi. Off-line and on-line quality control systems. In Proceedings of International Conference on Quality Control, 1978. Sheng-Ju Wu, Sheau-Wen Shiah, and Wei-Lung Yu. Parametric analysis of proton exchange membrane fuel cell performance by using the taguchi method and a neural network. Renewable Energy, 34(1):135144, 2009. doi:10.1016/j.renene.2008.03.006. Genichi Taguchi. Introduction to quality engineering: designing quality into products and processes. Technical report, 1986. doi:10.1002/qre.4680040216. Richard Horvath, Gyula Matyasi, and Agota Dregelyi-Kiss. Optimization of machining parameters for fine turning operations based on the response surface method. ANZIAM Journal, 55:250265, 2014. doi:10.21914/anziamj.v55i0.7865. Chuan-Tien Li, Sheng-Ju Wu, and Wei-Lung Yu. Parameter design on the multi-objectives of pem fuel cell stack using an adaptive neuro-fuzzy inference system and genetic algorithms. International Journal of Hydrogen Energy, 39(9):45024515, 2014. doi:10.1016/j.ijhydene.2014.01.034. Antoine Guisan, Thomas C Edwards Jr, and Trevor Hastie. Generalized linear and generalized additive models in studies of species distributions: setting the scene. Ecological modelling, 157(2-3):89100, 2002. doi:10.1016/S0304-3800(02)00204-1. Sheng Chen, Colin FN Cowan, and Peter M Grant. Orthogonal least squares learning algorithm for radial basis function networks. IEEE Transactions on neural networks, 2(2):302309, 1991. doi:10.1109/72.80341. Howard Demuth and Mark Beale. Neural network toolbox for use with matlab-user's guide verion 4.0. 1993. Janice Gaffney, Charles Pearce, and David Green. Binary versus real coding for genetic algorithms: A false dichotomy? ANZIAM Journal, 51:347359, 2010. doi:10.21914/anziamj.v51i0.2776. Daniel May and Muttucumaru Sivakumar. Techniques for predicting total phosphorus in urban stormwater runoff at unmonitored catchments. ANZIAM Journal, 45:296309, 2004. doi:10.21914/anziamj.v45i0.889. Chang-Xue Jack Feng, Zhi-Guang Yu, and Andrew Kusiak. Selection and validation of predictive regression and neural network models based on designed experiments. IIE Transactions, 38(1):1323, 2006. doi:10.1080/07408170500346378. Yin-Ying Fang, Ping-Jung Sung, Kai-An Cheng, Meng Fan Tsai, and Chifang Chen. Underwater radiated noise measurement of ocean researcher 3. In The 29th Taiwan Society of Naval Architects and Marine Engineers Conference, 2017. Yin-Ying Fang, Chi-Fang Chen, and Sheng-Ju Wu. Analysis of vibration and underwater radiated noise of ocean researcher 3. In The 30th Taiwan Society of Naval Architects and Marine Engineers Conference, 2018. Det Norske Veritas. Rules for classification of ships new buildings special equipment and systems additional class part 6 chapter 24 silent class notation. Rules for Classification of ShipsNewbuildings, 2010. Underwater acousticsquantities and procedures for description and measurement of underwater sound from ships-part 1requirements for precision measurements in deep water used for comparison purposes. (ISO 17208-1:2012), 2012. Bureau Veritas. Underwater radiated noise, rule note nr 614 dt r00 e. Bureau Veritas, 2014. R.J. Urick. Principles of underwater sound, volume 3. McGraw-Hill New York, 1983. Lars Burgstahler and Martin Neubauer. New modifications of the exponential moving average algorithm for bandwidth estimation. In Proc. of the 15th ITC Specialist Seminar, 2002. Bishnu Prasad Lamichhane. Removing a mixture of gaussian and impulsive noise using the total variation functional and split bregman iterative method. ANZIAM Journal, 56:5267, 2015. doi:10.21914/anziamj.v56i0.9316. Chao-Ton Su. Quality engineering: off-line methods and applications. CRC press, 2016. Jiju Antony and Mike Kaye. Experimental quality: a strategic approach to achieve and improve quality. Springer Science and Business Media, 2012. Ozkan Kucuk, Tayeb Elfarah, Serkan Islak, and Cihan Ozorak. Optimization by using taguchi method of the production of magnesium-matrix carbide reinforced composites by powder metallurgy method. Metals, 7(9):352, 2017. doi:10.3390/met7090352. G Taguchi. System of experimental design, quality resources. New York, 108, 1987. Gavin C Cawley and Nicola LC Talbot. Efficient leave-one-out cross-validation of kernel fisher discriminant classifiers. Pattern Recognition, 36(11):25852592, 2003. doi:10.1016/S0031-3203(03)00136-5.

Style APA, Harvard, Vancouver, ISO itp.

31

Hu, Xichun, Qingyuan Zhang, Shusen Wang, Tao Sun, Xiaohua Zeng, Weimin Xie, Zhongsheng Tong i in. "Abstract PO1-29-03: Efficacy, Safety, and Immunogenicity of TQ-B211 (a Trastuzumab Biosimilar) Plus Docetaxel versus Herceptin® Plus Docetaxel for HER2-positive Metastatic Breast Cancer: a Double-blind, Randomised, Multicenter, Phase 3 Trial". Cancer Research 84, nr 9_Supplement (2.05.2024): PO1–29–03—PO1–29–03. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-29-03.

Pełny tekst źródła

Streszczenie:

Abstract Background: Breast cancer is one of the most common malignant tumors in women worldwide. In China, the incidence of breast cancer has been steadily increasing. Approximately 30% of human breast cancers exhibit human epidermal growth factor receptor 2 (HER2) positivity, which is closely associated with tumor aggressiveness, high recurrence rate and high mortality. This study aimed to evaluate the efficacy, safety, and immunogenicity of TQ-B211 (a trastuzumab biosimilar) compared to the reference trastuzumab in combination with docetaxel as first-line treatment for patients with HER2-positive metastatic breast cancer. Methods: This randomized, multicenter, double-blind phase III equivalence study enrolled HER2+ metastatic breast cancer patients aged 18-75, ECOG PS ≤1, no prior systemic chemotherapy, biologic, or targeted therapy for recurrent or metastatic disease, and at least one measurable lesion (RECIST 1.1). The patients were randomly assigned to two groups: the experimental group received TQ-B211 (8 mg/kg iv on day 1, cycle 1, followed by 6 mg/kg q3w for cycles 2-8) in combination with docetaxel (75 mg/m2 on day 2, cycle1, followed by 75 mg/m2 on day 1 for cycles 2-8), while the control group received Herceptin® in combination with docetaxel. For subjects who completed 8 cycles of treatment without disease progression and demonstrated tolerability, they were subsequently administered TQ-B211 as monotherapy until disease progression or unsuitable for further treatment. The primary efficacy endpoint was ORR up to week 24 (ORR24w). Equivalence was declared if the 90% confidence interval (CI) of relative ratio (RR) value was within the range of 0.8 to 1.25. Secondary efficacy endpoints included duration of response (DoR); progression-free survival (PFS); disease control rate (DCR); overall survival (OS), safety and immunogenicity. Results: Between December 6, 2018 and July 31, 2021, a total of 386 patients (pts) were enrolled (192 pts in the TQ-B211 group and 194 pts in the Herceptin® group). In the intention-to-treat (ITT) population, the ORR24w of the TQ-B211 group was 67.19% (95% CI: 60.55, 73.83), while the ORR24w of the Herceptin® group was 65.98% (95% CI: 59.31, 72.65). The RR of the confirmed ORR24w between the two groups was 1.02 (90%CI, 0.90, 1.15), which fell entirely in the predefined equivalence margins (0.8, 1.25), indicating comparable efficacy of the two drugs. In the ITT population, the DCR of the TQ-B211 group and the Herceptin® group were 83.85% (78.65, 89.06) and 78.35% (72.56, 84.15) respectively, with no statistically significant difference between the two groups (P=0.1940). By the data cutoff date of October 31, 2021, the median PFS was not statistically different (P=0.6834); the median OS was not reached in both groups (P=0.9246). Additionally, the data results of the per-protocol (PP) population were similar to those of the ITT population. In total, similar rates of treatment-related grade ≥3 adverse events (41.05% vs. 46.39%) occurred in the TQ-B211 and Herceptin® groups, respectively. The incidence and magnitude of immunogenicity were low in both of the two groups (ADA: 0.53% vs. 0%, Nab: both negative). Conclusion: Equivalence for efficacy was demonstrated between TQ-B211 and Herceptin® on the basis of ORR24w. Safety and immunogenicity were comparable. Citation Format: Xichun Hu, Qingyuan Zhang, Shusen Wang, Tao Sun, Xiaohua Zeng, Weimin Xie, Zhongsheng Tong, Hui Cao, Huihua Xiong, Xiuwen Wang, Jin Yang, Shuqun Zhang, Ying Wang, Chunhong Hu, Kaijian Lei, Binlin Ma, Wei Liu, Zhiyong Yu, PeiJian Peng, Hongwei Yang, Zhijun Yuan, Xiaojia Wang, Xujuan Wang, Hong Wang, Yongqian Shu, Nanlin Li, Wenbin Yue, Jingfen Wang, Daqing Wang, Zhiguo Luo, Junyang Mo, Yarong Li, Lili Sheng. Efficacy, Safety, and Immunogenicity of TQ-B211 (a Trastuzumab Biosimilar) Plus Docetaxel versus Herceptin® Plus Docetaxel for HER2-positive Metastatic Breast Cancer: a Double-blind, Randomised, Multicenter, Phase 3 Trial [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-29-03.

Style APA, Harvard, Vancouver, ISO itp.

32

Li, Rongrong, Namratha Sheshadri, Jianliang Shen, Junrong Yan, Jaeyong Jung, Muhammad Usama Tariq, Y. Lynn Wang, Ping Xie i Wei-Xing Zong. "Abstract PO-020: ZBTB24 is a novel tumor suppressor and cooperates with CDKN2A to suppress B-cell lymphomagenesis". Blood Cancer Discovery 5, nr 3_Supplement (19.06.2024): PO—020—PO—020. http://dx.doi.org/10.1158/2643-3249.lymphoma24-po-020.

Pełny tekst źródła

Streszczenie:

Abstract B-cell lymphoma is the most common hematological malignancy that accounts for the sixth highest mortality among all cancers. Despite recent improvements on combined chemotherapy and immunotherapy, treatments remain challenging due to complex genetic heterogeneity and molecular pathogenesis. To explore novel mechanisms in B-cell lymphomagenesis, we performed a genome-wide CRISPR knockout screen in the murine interleukin-3 (IL-3)-dependent Ba/F3 pro-B cell line and identified Zbtb24 as a putative target whose silencing leads to elevated proliferative signaling and reduced apoptosis, conferring IL-3-independent growth in Ba/F3 cells. Silencing of ZBTB24 also accelerated growth in multiple human B-cell lymphoma cell lines. ZBTB24 is a member of the zinc-finger and BTB domain containing transcription factor that is highly expressed in spleen and bone marrow. While it has been shown that ZBTB24 may play an important role in B-cell development and activation, its involvement in B-cell lymphoma has not been described. Analysis of publicly available datasets found that ZBTB24 copy number deletion occurs in various B-cell lymphomas, which frequently co-occurs with deletion of the tumor suppressor CDKN2A. Hence, we generated B-cell specific Zbtb24 single knockout and Zbtb24/Cdkn2a double knockout mice to explore the role of Zbtb24 in vivo. While Zbtb24 and Cdkn2a single knockout mice remained tumor-free or showed low penetrance of tumorigenesis, the double knockout mice developed lymphadenopathy and splenomegaly accompanied with accelerated mortality. Flow cytometry analysis of bone marrow, spleen, and lymph nodes revealed malignant B-cells. Subsequent transplantation of the splenic cells induced identical malignant B-cell lymphomagenesis and immunophenotype in athymic nude mice, further confirming its malignant identity. These results indicate that ZBTB24 is a novel tumor suppressor in B-cell malignancy. Ongoing studies are being conducted to understand the mechanistic basis for ZBTB24 tumor suppressive function that may involve transcriptional regulation of its target gene expression. This project is supported by the NIH R01CA232246, R01CA129536, and the John Colaizzi Endowment Fund. Citation Format: Rongrong Li, Namratha Sheshadri, Jianliang Shen, Junrong Yan, Jaeyong Jung, Muhammad Usama Tariq, Y Lynn Wang, Ping Xie, Wei-Xing Zong. ZBTB24 is a novel tumor suppressor and cooperates with CDKN2A to suppress B-cell lymphomagenesis [abstract]. In: Proceedings of the Fourth AACR International Meeting on Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application; 2024 Jun 19-22; Philadelphia, PA. Philadelphia (PA): AACR; Blood Cancer Discov 2024;5(3_Suppl):Abstract nr PO-020.

Style APA, Harvard, Vancouver, ISO itp.

33

Zhao, Dongni, Shaohua Zhang, Chun Lin, Jiefeng Ye, Yue Chen, Jian-Min Zhang, Jianmin Tao i in. "Covalent Heterojunctions Enhance Bi₂S₃/Reduced Graphene Oxide (rGO) Nanocomposite Performance as Aqueous Zinc Ion Battery Material". ECS Meeting Abstracts MA2023-01, nr 4 (28.08.2023): 837. http://dx.doi.org/10.1149/ma2023-014837mtgabs.

Pełny tekst źródła

Streszczenie:

The shortage of lithium resources, safety and recycling difficulty has focused attention on alternative energy storage devices in recent years. The aqueous zinc-ion battery (ZIB) stands out against such a background because of its earth abundance, safety, and environmental friendliness.1 However, the limited choice of cathode materials hinders the development of advanced high-energy-density aqueous ZIBs. At present, manganese oxide2 and vanadium oxide3 are the two most widely studied zinc-ion battery cathodes, but the migration of Zn2+ in these materials is limited by the strong electrostatic interaction with lattice oxygen ions, resulting in poor reversible capacity. Metal sulfides, instead, may effectively improve the electrochemical performance reversibility of ZIBs. Layered metal sulfides have been extensively studied in monovalent cation (Li+, Na+, K+) rechargeable batteries.4 However, although limited studies with Bi2S3 5,6 as ZIB cathode material exist, their detailed electrochemical charge storage and transfer mechanisms are not well understood. In this work, we explore the effect of covalent anchoring Bi2S3 on reduced graphene oxide (rGO) on the stability and cycling performance as a cathode for aqueous ZIBs. During the hydrothermal synthesis, the reduced graphene oxide serves as the nucleation substrate enabling the formation of fine and uniformly sized Bi2S3 grains, Figure 1 (a). Raman and X-ray photoelectron spectroscopy (XPS) confirm the formation of Bi-O-C heterojunctions during hydrothermal synthesis. These oxygen bridges serve as efficient electron transfer channels in the Bi2S3/rGO composite for rapid charge compensation during Zn2+ incorporation/extraction. As a result, Bi2S3/rGO composite shows notably better rate performance and cycling stability compared with pristine Bi2S3. The specific capacity of Bi2S3-rGO8 composite is ~186 mAh g-1 at the current density of 500 mA g-1 after 150 cycles, considerably higher than unsupported Bi2S3. Additionally, the Bi2S3 nucleated on GO with smaller particle sizes can shorten the transport path of zinc ions, which is beneficial for fast charge transfer. Therefore, Bi2S3-rGO8 can deliver more than 100 mAh g-1 at 10 A/g charge/discharge current density, Figure 1 (b). Also, the zinc storage mechanism was analyzed by X-ray diffraction spectroscopy (XRD) and XPS, indicating a reversible conversion reaction of Zn2+ in the Bi2S3-rGO framework. During discharging, Zn2+ is embedded in Bi2S3-rGO frame to form ZnS and Bi wrapped in rGO. The process is accompanied by the dissolution of bismuth into electrolyte and the formation of (ZnSO4)[Zn(OH)2]3·5H2O (ZHS) on the electrode surface. Inhibition of these two processes may further increase the cycle stability of Bi2S3-rGO. Rotating ring disc electrode (RRDE) measurements, in which we detect dissolved Bi, indicate that Bi dissolution in the electrolyte during charging/discharging is mitigated in Bi2S3/rGO electrode, compared to pristine Bi2S3. References: Z. Li, L. Wu, S. Dong, T. Xu, S. Li, Y. An, J. Jiang and X. Zhang, Adv. Funct. Mater., 2021, 31, 2006495. J. Long, Z. Yang, F. Yang, J. Cuan and J. Wu, Electrochim. Acta, 2020, 344, 136155. Wu, Y. Ding, L. Hu, X. Zhang, Y. Huang and S. Chen, Mater. Lett., 2020, 277, 128268. Z. Hu, Q. Liu, S. Chou and S. Dou, Adv. Mater., 2017, 29, 1700606. S. Li, Y. Liu, X. Zhao, K. Cui, Q. Shen, P. Li, X. Qu and L. Jiao, Angew. Chem., Int. Ed., 2021, 60, 20286–20293. T. Xiong, Y. Wang, B. Yin, W. Shi, W. S. V. Lee and J. Xue, Nano-Micro Lett., 2020, 12, 8. Figure 1

Style APA, Harvard, Vancouver, ISO itp.

34

Huang, Hao, i Kaiying Wang. "2D Metal Covalent Organic Frameworks Towards Electrochemical Catalysis". ECS Meeting Abstracts MA2023-02, nr 57 (22.12.2023): 2757. http://dx.doi.org/10.1149/ma2023-02572757mtgabs.

Pełny tekst źródła

Streszczenie:

In the past century, innovative electrochemical reactions with low-consumption and environmental-friend have been a key substance for worldwide chemical industry.[1] Nowadays, the majority of the electrochemical reactions rely on low-cost and high-efficient catalysts, and there is an ever-growing need for the development of advanced catalysts to secure a sustainable future for our society.[2] The pursuit for sustainable energy stimulates the innovative concepts of advanced catalytic materials for electrochemical reactions, such as metal-air battery, nitrogen fixation and carbon neutrality etc.[3] The electrocatalysts play a vital role to promote the renewable energy conversion efficiencies and system performance.[4] However, the electrocatalytic activities of most inorganic catalysts arises from the unsaturated metal sites exposed on the surfaces or edges, and the internal metal atoms in bulk phase are totally inert, resulting in the low utilization and efficiency of metal atoms for electrocatalysis.[5] Exploring novel electrocatalysts with high metal utilization is essential for electrochemical reactions. Recently, single-atom catalysts (SACs) strategy has been proposed to promote the efficiency and utilization of metal atoms in electrocatalysts. In particular, SACs could provide an ideal approach to maximize the efficiency of active metal atom utilization (in principle, up to 100%) and lower the cost of the electrochemical reactions.[6] Inspired by SACs strategy, metal covalent-organic-frameworks (MCOFs) can be emerged as efficient catalysts, due to the numerous single-atom sites, ordered in-plane porous structure and outstanding stable framework. We propose a novel two-dimensional MCOFs, constructed by porphyrin subgroup (Figure 1), for achieving high efficiency of electrochemical reactions. Porphyrinsubgroup is a type of heterocyclic molecules with conjugated structure, which has strong ability to coordinate almost all transition metal ions to form high active single-metal sites. Thus, MCOFs with porphyrin could be a promising next-generation electrocatalyst, and an ideal catalytic model to reveal the mechanism of electrochemical reactions. Acknowledgments: The authors gratefully acknowledge the financial support from H2020 Marie Skłodowska-Curie Actions (101024758) and National Natural Science Foundation of China (22002083). References [1] X. X. Zou, and Y. Zhang, Chem. Soc. Rev., 44, 5148-5180 (2015). [2] S. L. Foster, S. I. Perez Bakovic, R. D. Duda, S. Maheshwari, R. D. Milton, S. D. Minteer, M. J. Janik, J. N. Renner, L. F. Greenlee,Nat. Catal., 1, 490-500 (2018). [3] C. Zhang, X. Liang, R. Xu, C. Dai, B. Wu, G. Yu, B. Chen, X. Wang, N. Liu, Adv. Funct. Mater, 31, 2008298 (2021). [4] Y. Wang, H. Su, Y. He, L. Li, S. Zhu, H. Shen, P. Xie, X. Fu, G. Zhou, C. Feng, D. Zhao, F. Xiao, X. Zhu, Y. Zeng, M. Shao, h. Chen, G. Wu, J. Zeng, C. Wang, Chem. Rev., 120, 12217-12314 (2020). [5] M. D. Hossain, Z. Liu, M. Zhuang, X. Yan, G.-L. Xu, C. A. Gadre, A. Tyagi, I. H. Abidi, C.-J. Sun, H. Wong, A. Guda, Yufeng Hao, X. Pan, K. Amine, Z. Luo, Adv. Energy Mater., 9, 1803689 (2019). [6] J. Yang, W. Li, D. Wang, Y. Li, Adv. Mater., 32, 2003300 (2020). Figure 1

Style APA, Harvard, Vancouver, ISO itp.

35

Zazyki de Almeida, Rafaela, Maísa Casarin, Bruna Oliveira de Freitas i Francisco Wilker Mustafa Gomes Muniz. "Medo e ansiedade de estudantes de Odontologia diante da pandemia do novo coronavírus: um estudo transversal". ARCHIVES OF HEALTH INVESTIGATION 9, nr 6 (20.12.2020): 623–28. http://dx.doi.org/10.21270/archi.v9i6.5243.

Pełny tekst źródła

Streszczenie:

Objetivo: Esse estudo objetivou investigar percepções de estudantes de Odontologia quanto ao medo e à ansiedade em relação ao manejo de pacientes e ao risco de infecção por COVID-19. Materiais e métodos: Esse estudo transversal envolveu todos os alunos regularmente matriculados em Odontologia, no primeiro semestre de 2020, da Universidade Federal de Pelotas. Um questionário foi aplicado, coletando dados demográficos, nível de formação e perguntas relacionadas ao medo e ansiedade frente à pandemia de COVID-19. Quatro comparações de acordo com a fase da graduação (fase pré-clínica ou clínica), nível de graduação e pós-graduação e de acordo com os sexos foram feitas. Análises independentes para as comparações entre os sexos foram realizadas para os alunos de graduação e de pós-graduação (α<5%). Resultados: Foram incluídos 408 estudantes. Na graduação, mulheres relataram sentirem-se mais ansiosas ao realizar tratamento em pacientes com suspeita de COVID-19 (54%) e sentem mais medo ao ouvir que a infecção tem causado mortes (92,4%), na pós-graduação, responderam ser mais nervosas para conversar com pacientes em ambientes fechados em comparações com homens (P<0,05). Alunos em fase pré-clínica possuem significativamente menor receio (65,5%), ansiedade (32,3%) e nervosismo (28,3%) do contágio do COVID-19 quando comparados com aqueles na fase clínica. Conclusões: Mulheres e alunos na fase clínica apresentam maior ansiedade e nervosismo. Descritores: Ansiedade; Estudantes de Odontologia; Medo; Infecções por Coronavírus. Referências Chang J, Yuan Y, Wang D. [Mental health status and its influencing factors among college students during the epidemic of COVID-19]. Nan Fang Yi Ke Da Xue Xue Bao. 2020;40(2):171-176. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19- 11 March 2020. 2020. Disponível em: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Acesso em: 8 de novembro de 2020. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, Scarlata S, Agrò FE. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288(2):192-206. Chen E, Lerman K, Ferrara E. Tracking Social Media Discourse About the COVID-19 Pandemic: Development of a Public Coronavirus Twitter Data Set. JMIR Public Health Surveill. 2020;6(2):e19273. Iyer P, Aziz K, Ojcius DM. Impact of COVID-19 on dental education in the United States. J Dent Educ. 2020;84(6):718-722. Meng L, Hua F, Bian Z. Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine. J Dent Res. 2020;99(5):481-487. Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci. 2020;12(1):9. Machado RA, Bonan PRF, Perez DEDC, Martelli Júnior H. COVID-19 pandemic and the impact on dental education: discussing current and future perspectives. Braz Oral Res. 2020;34:e083. Ataş O, Talo Yildirim T. Evaluation of knowledge, attitudes, and clinical education of dental students about COVID-19 pandemic. PeerJ. 2020;8:e9575. Deery C. The COVID-19 pandemic: implications for dental education. Evid Based Dent. 2020;21(2):46-47. Basudan S, Binanzan N, Alhassan A. Depression, anxiety and stress in dental students. Int J Med Educ. 2017;8:179-186. Elani HW, Allison PJ, Kumar RA, Mancini L, Lambrou A, Bedos C. A systematic review of stress in dental students. J Dent Educ. 2014; 78(2):226-42. Sahu P. Closure of Universities Due to Coronavirus Disease 2019 (COVID-19): Impact on Education and Mental Health of Students and Academic Staff. Cureus. 2020;12(4):e7541. Ahmed MA, Jouhar R, Ahmed N, Adnan S, Aftab M, Zafar MS, Khurshid Z. Fear and Practice Modifications among Dentists to Combat Novel Coronavirus Disease (COVID-19) Outbreak. Int J Environ Res Public Health. 2020;17(8):2821. Talevi D, Socci V, Carai M, Carnaghi G, Faleri S, Trebbi E, di Bernardo A, Capelli F, Pacitti F. Mental health outcomes of the CoViD-19 pandemic. Riv Psichiatr. 2020;55(3):137-44. Mijiritsky E, Hamama-Raz Y, Liu F, Datarkar AN, Mangani L, Caplan J, Shacham A, Kolerman R, Mijiritsky O, Ben-Ezra M, Shacham M. Subjective Overload and Psychological Distress among Dentists during COVID-19. Int J Environ Res Public Health. 2020;17:5074. Rymarowicz J, Stefura T, Major P, Szeliga J, Wallner G, Nowakowski M, Pędziwiatr M. General surgeons' attitudes towards COVID-19: A national survey during the SARS-CoV-2 virus outbreak. Eur Surg. 2020;1-6. Adams JG, Walls RM. Supporting the Health Care Workforce During the COVID-19 Global Epidemic. JAMA. 2020;323(15):1439-40. Naz N, Iqbal S, Mahmood A. Stress, anxiety and depression among the dental students of university college of medicine and dentistry Lahore; Pakistan. Pak J Med Health Sci. 2017;11(4):1277-81. Waqas A, Iftikhar A, Malik Z, Aedma KK, Meraj H, Naveed S. Association of severity of depressive symptoms with sleep quality, social support and stress among Pakistani medical and dental students: A cross-sectional study. Global Psychiatry. 2019;2(2):211-20. Wang Y, Di Y, Ye J, Wei W. Study on the public psychological states and its related factors during the outbreak of coronavirus disease 2019 (COVID-19) in some regions of China. Psychol Health Med. 2020;1-10. Xiong J, Lipsitz O, Nasri F, Lui LMW, Gill H, Phan L, Chen-Li D, Iacobucci M, Ho R, Majeed A, McIntyre RS. Impact of COVID-19 pandemic on mental health in the general population: A systematic review. J Affect Disord. 2020;277:55-64. Liu N, Zhang F, Wei C, Jia Y, Shang Z, Sun L, Wu L, Sun Z, Zhou Y, Wang Y, Liu W. Prevalence and predictors of PTSS during COVID-19 outbreak in China hardest-hit areas: Gender differences matter. Psychiatry Res. 2020;287;112921. Terán E, Mayta-Tovalino F. Risk Factors, Self-perceived Stress, and Clinical Training among Dentistry Students in Peru: A Cross-sectional Study. J Contemp Dent Pract. 2019;20(5):561-5. Uraz A, Tocak YS, Yozgatligil C, Cetiner S, Bal B. Psychological well-being, health, and stress sources in Turkish dental students. J Dent Educ. 2013:77(10):1345-55. Agius AM, Gatt G, Vento Zahra E, Busuttil A, Gainza-Cirauqui ML, Cortes ARG et al. Self-reported dental student stressors and experiences during the COVID-19 pandemic. J Dent Educ. 2020. doi: 10.1002/jdd.12409. Hu J, Zou H, Dai Y, Feng Z. How to keep students engaged in oral health education during the COVID-19 pandemic. J Dent Educ. 2020. doi: 10.1002/jdd.12420. Liu S, Yang L, Zhang C, Xiang YT, Liu Z, Hu S, Zhang B. Online mental health services in China during the COVID-19 outbreak. Lancet Psychiatry. 2020;7(4):e17-8. Maia BR, Dias PC. Anxiety, depression and stress in university students: the impact of COVID-19. Estudos de Psicologia (Campinas). 2020;37:e200067.

Style APA, Harvard, Vancouver, ISO itp.

36

Orbai, A. M., L. C. Coates, A. Deodhar, P. Helliwell, C. T. Ritchlin, A. Kollmeier, E. C. Hsia i in. "POS1029 GUSELKUMAB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENTS IN GENERAL HEALTH OUTCOMES MEASURED WITH PROMIS-29 THROUGH 52 WEEKS: RESULTS FROM THE PHASE 3 DISCOVER-1 TRIAL". Annals of the Rheumatic Diseases 80, Suppl 1 (19.05.2021): 785–86. http://dx.doi.org/10.1136/annrheumdis-2021-eular.471.

Pełny tekst źródła

Streszczenie:

Background:In the DISCOVER-1 study, the interleukin-23 p19 subunit inhibitor guselkumab (GUS) demonstrated robust efficacy across joint and skin clinical manifestations of psoriatic arthritis (PsA).1 Patients (pts) with PsA also experience a broad range of symptoms that negatively impact health-related quality of life (eg, pain, fatigue, anxiety, depression, sleep disturbance, poor physical function).2Objectives:Assess the treatment effect of GUS on general health outcomes in pts with PsA in the DISCOVER-1 trial through Week (W) 52 using the Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) instrument.Methods:Pts with active PsA (≥3 swollen + ≥3 tender joints; C-reactive protein ≥0.3 mg/dL) and inadequate response to standard conventional therapies were randomized 1:1:1 to GUS 100 mg Q4W; GUS 100 mg at W0, W4, then Q8W; or placebo (PBO). PBO pts switched to GUS 100 mg Q4W at W24. PROMIS-29 contains 4 items for each of 7 domains (anxiety, depression, fatigue, pain interference, physical function, sleep disturbance, social participation) and 1 pain intensity item; 28 items are scored on a 5-point Likert-type scale, and pain intensity is rated from 0-10. The raw score of each domain is converted to a standardized T-score, with norms based on a general population mean score=50 and a standard deviation (SD)=10. Higher scores in anxiety, depression, fatigue, pain interference, and sleep disturbance indicate more severe symptoms; higher physical function and social participation scores indicate better health outcomes. Changes ≥5 points (1/2 SD of T-score) are considered clinically meaningful. Analyses were performed using both observed (mean scores/changes, effect sizes) and imputed (clinically meaningful response, whereby change from baseline was set to 0 at W24/52 for pts who had missing data or at W24 for pts who met treatment failure criteria prior to W24).Results:At baseline, mean PROMIS-29 T-scores for physical function, social participation, sleep disturbance, pain, and fatigue were worse in the 381 PsA pts enrolled in DISCOVER-1 than in the general US population. Across all 7 domains, observed mean PROMIS-29 T-scores showed improvements in GUS-treated pts from baseline to W24 and W52 (Figure 1). Observed mean changes from baseline to W24 and W52, with calculated effect size, are shown (Table 1). In all pts, including those with imputed data, significantly higher percentages of pts in both GUS treatment groups vs PBO had ≥5-point improvements in fatigue, pain interference, physical function, sleep disturbance, social participation, and pain intensity domains at W24 (all nominal p<0.05). Mean improvements in PROMIS-29 domains were maintained through W52.Conclusion:In pts with active PsA, PROMIS-29 results indicate that GUS treatment was associated with clinically meaningful reductions in fatigue and pain and improvement in physical function and social participation, which were maintained through 1 year.References:[1] Deodhar A et al. Lancet. 2020;395:1115-25.[2] Orbai A et al. Ann Rheum Dis. 2017;76:673-80.Table 1.Mean Change and Effect Size of Change From Baseline in PROMIS-29 Domain Scores at W24 and W52 (Observed)Mean Change From Baseline [Effect Size]GUS Q4WGUS Q8WPBOW0-24GUS Q4WW24-52W24W52W24W52W24W52Anxiety−3.1 [−0.3]−3.1 [−0.3]−3.7 [−0.4]−4.3 [−0.5]−1.5 [−0.2]−3.6 [−0.4]Depression−2.7 [−0.3]−3.0 [−0.4]−4.0 [−0.4]−4.0 [−0.4]−0.6 [−0.1]−2.5 [−0.3]Fatigue−4.8 [−0.5]−5.6 [−0.6]−4.8 [−0.5]−6.8 [−0.7]−2.1 [−0.2]−5.7 [−0.6]Pain interference−5.4 [−0.8]−6.2 [−1.0]−5.8 [−1.0]−7.0 [−1.1]−2.8 [−0.4]−6.3 [−1.0]Physical function5.0 [0.8]5.9 [0.9]4.1 [0.6]5.0 [0.7]1.7 [0.2]4.2 [0.6]Sleep disturbance−2.5 [−0.4]−3.9 [−0.6]−3.8 [−0.6]−4.4 [−0.6]−1.5 [−0.2]−3.3 [−0.5]Social participation4.2 [0.5]5.3 [0.7]5.3 [0.6]6.6 [0.8]1.7 [0.2]4.9 [0.6]Pain intensity*−2.3 [−1.2]−2.8 [−1.5]−2.1 [−1.1]−2.7 [−1.4]−0.7 [−0.4]−2.5 [−1.3]*Raw score; all other domains reported as T-score.Disclosure of Interests:Ana-Maria Orbai Consultant of: Eli Lilly, Janssen, Novartis, Pfizer, UCB, Grant/research support from: Abbvie, Eli Lilly and Company, Celgene, Novartis, Janssen, Horizon, Laura C Coates Consultant of: AbbVie, Amgen, Biogen, Bristol Myers Squibb, Boehringer Ingelehim, Celgene, Domain, Eli Lilly, Gilead, Janssen, Medac, Novartis, Pfizer and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Novartis, Pfizer, Atul Deodhar Speakers bureau: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, GSK, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB, Philip Helliwell Consultant of: Galapagos, Janssen, and Novartis, Grant/research support from: Abbvie, Janssen, and Pfizer, Christopher T. Ritchlin Consultant of: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB Pharma, Grant/research support from: AbbVie, Amgen, UCB Pharma, Alexa Kollmeier Shareholder of: Johnson & Johnson, of which Janssen Research & Development, LLC is a wholly owned subsidiary, Employee of: Janssen Research & Development, LLC, Elizabeth C Hsia Shareholder of: Johnson & Johnson, of which Janssen Research & Development, LLC is a wholly owned subsidiary, Employee of: Janssen Research & Development, LLC, Xie L Xu Shareholder of: Johnson & Johnson, of which Janssen Research & Development is a wholly owned subsidiary, Employee of: Janssen Research & Development, LLC, Shihong Sheng Shareholder of: Johnson & Johnson, of which Janssen Research & Development, LLC is a wholly owned subsidiary, Employee of: Janssen Research & Development, LLC, Yusang Jiang Employee of: Cytel, Inc., providing statistical support (funded by Janssen), Yan Liu Shareholder of: Johnson & Johnson, of which Janssen Research & Development, LLC is a wholly owned subsidiary, Employee of: Janssen Research & Development, LLC, Chenglong Han Shareholder of: Johnson & Johnson, of which Janssen Research & Development, LLC is a wholly owned subsidiary, Employee of: Janssen Research & Development, LLC.

Style APA, Harvard, Vancouver, ISO itp.

37

Mease, P. J., P. Foley, K. Reich, J. Bagel, M. Lebwohl, Y. W. Yang, M. Shawi i in. "POS1031 LOW INCIDENCE OF GASTROINTESTINAL-RELATED AND OVERALL SERIOUS ADVERSE EVENTS AMONG GUSELKUMAB-TREATED PATIENTS: POOLED ANALYSES OF VOYAGE 1 & 2 AND DISCOVER 1 & 2 THROUGH 1-YEAR". Annals of the Rheumatic Diseases 80, Suppl 1 (19.05.2021): 787–88. http://dx.doi.org/10.1136/annrheumdis-2021-eular.558.

Pełny tekst źródła

Streszczenie:

Background:Guselkumab (GUS), a human monoclonal antibody that specifically binds to the p19-subunit of interleukin (IL)-23, demonstrated efficacy in the Phase 3 VOYAGE 1&2 trials of patients (pts) with moderate to severe plaque psoriasis (PsO)1,2 and in the DISCOVER 1&2 trials of pts with active psoriatic arthritis (PsA).3,4 IL-17 inhibitors used to treat PsO and PsA have been associated with exacerbation or new onset of inflammatory bowel disease (IBD) (e.g., Crohn’s disease or ulcerative colitis).5Objectives:Evaluate the incidence of gastrointestinal (GI)-related and overall serious adverse events (SAEs) from pooled safety data through 1-year of GUS 100 mg treatment from the VOYAGE 1&2 and DISCOVER 1&2 trials.Methods:Using pooled safety data from the VOYAGE 1&2 PsO trials and DISCOVER 1&2 PsA trials, SAEs related to GI disorders were identified using the Medical Dictionary for Regulatory Activities (MedDRA) system-organ class “GI disorders”. Pts with a previous history of IBD were not excluded in these trials; medical history of IBD was collected at baseline in DISCOVER 1&2. Rates of overall SAEs and GI-related SAEs were calculated as the number of SAEs per 100 pt-years (PY) of follow-up (95% confidence intervals). Data are presented for the placebo (PBO)-controlled period (Weeks 0-16 for VOYAGE 1&2; Weeks 0-24 for DISCOVER 1&2) and through 1-year (defined as through Week 48 for VOYAGE 1&2; through Week 60 for DISCOVER 1, and through Week 52 for DISCOVER 2). Events of uveitis and opportunistic infections were also analyzed.Results:Through the PBO-controlled period, the overall rates of GI-related SAEs per 100 PY for pooled VOYAGE 1&2 were: PBO 0.78 (0.02, 4.34), GUS q8w 0; and for pooled DISCOVER 1&2: PBO 0.58 (0.01, 3.23), GUS q8w 0.58 (0.01, 3.21), GUS q4w 0. The GI-related SAEs included: gastrointestinal hemorrhage (PBO; n=1) for pooled VOYAGE 1&2; and inflammatory bowel disease (PBO; n=1) and mechanical ileus (GUS q8w; n=1) for pooled DISCOVER 1&2. Through 1-year, the overall rates of GI-related SAEs for pooled VOYAGE 1&2 were: Combined GUS group (GUS q8w and PBO→GUS groups) 0.51 (0.17, 1.20); and for pooled DISCOVER 1&2: GUS q8w 0.52 (0.06, 1.88), GUS q4w 0, Combined GUS group (GUS q8w, GUS q4w, and PBO→GUS groups) 0.21 (0.02, 0.74). The GI-related SAEs in the Combined GUS group for pooled VOYAGE 1&2 included: gastritis, hemorrhoids, inguinal hernia, pancreatitis, and umbilical hernia (0.10/100PY [0.00, 0.57]; n=1 for each); and in the Combined GUS group for pooled DISCOVER 1&2: mechanical ileus and pancreatitis chronic (0.10/100PY [0.00, 0.57]; n=1 for each). Overall, no cases of exacerbation or new onset of IBD were reported in GUS-treated pts, including 2 pts with a prior history of IBD in DISCOVER 1&2 (total PY of follow-up for the Combined GUS groups in VOYAGE and DISCOVER were 974 and 973, respectively). Through the PBO-controlled period, rates of overall SAEs for GUS-treated pts were comparable to PBO-pts and SAE rates remained low through 1-year of follow-up in the VOYAGE 1&2 and DISCOVER 1&2 trials. There were no reported cases of uveitis, opportunistic infections, or tuberculosis in GUS-treated pts through 1-year.Conclusion:Through 1-year of follow-up with GUS treatment in pooled VOYAGE 1&2 and DISCOVER 1&2, GI-related SAE rates were low. There were no reported cases of uveitis, opportunistic infections, or new onset/exacerbation of IBD in GUS-treated pts. No new safety concerns were identified through 1-year.References:[1]Blauvelt A., et al. J Am Acad Dermatol. 2017;76:405-17.[2]Reich K., et al. J Am Acad Dermatol. 2017;76:418-31.[3]Deodhar A., et al. Lancet. 2020;395:1115-25.[4]Mease P.J., et al. Lancet. 2020; 395:1126-36.[5]Hohenberger M., et al. J Dermatolog Treat. 2018;29:13-8.Disclosure of Interests:Philip J Mease Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN, and UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, SUN, and UCB, Peter Foley Speakers bureau: AbbVie, Celgene, Janssen, Lilly, Merck, Novartis, Pfizer, Valeant, Galderma, GSK, Leo Pharma, and Roche, Consultant of: Janssen, Lilly, Novartis, Pfizer, Galderma, AbbVie, Amgen, AstraZeneca, Arcutis, Aslan, Boehringer Ingelheim, Celgene, Hexima, Merck, Sun Pharma, UCB Pharma, Valeant, BMS, Celtaxsys, CSL, Cutanea, Dermira, Genentech, GSK, Leo Pharma, Regeneron Pharmaceuticals Inc, Reistone, Roche, and Sanofi, Grant/research support from: AbbVie, Amgen, Celgene, Janssen, Leo Pharma, Lilly, Merck, Novartis, Pfizer, Sanofi, and Sun Pharma; travel grants from AbbVie, Janssen, Lilly, Merck, Novartis, Pfizer, Galderma, Leo Pharma, Roche, Sun Pharma, and Sanofi, Kristian Reich Consultant of: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB Pharma, Grant/research support from: AbbVie, Amgen, and UCB Pharma, Jerry Bagel Speakers bureau: AbbVie, Celgene Corporation, Eli Lilly, Janssen Biotech, and Novartis, Consultant of: AbbVie, Amgen, Celgene Corporation, Eli Lilly and Company, Janssen Biotech, Leo Pharma, Novartis, Sun Pharmaceutical Industries Ltd, and Valeant Pharmaceuticals, Grant/research support from: AbbVie, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Corrona, LLC, Dermavant Sciences, LTD, Dermira/UCB, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd, Janssen Biotech, Kadmon Corporation, Leo Pharma, Lycera Corp, Menlo Therapeutics, Novartis, Pfizer, Regeneron Pharmaceuticals, Sun Pharma, Taro Pharmaceutical Industries Ltd, and Valeant Pharmaceuticals, Mark Lebwohl Consultant of: Aditum Bio, Allergan, Almirall, Arcutis, Inc., Avotres Therapeutics, BirchBioMed Inc., BMD skincare, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Evommune, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy’s Laboratories, Serono, Theravance, and Verrica, Grant/research support from: Abbvie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly, Evommune, Incyte, Janssen, Leo Pharmaceutucals, Ortho Dermatologics, Pfizer, and UCB, Ya-Wen Yang Shareholder of: Johnson & Johnson, Employee of: Janssen Global Services, LLC, May Shawi Shareholder of: Johnson & Johnson, Employee of: Janssen Global Services, LLC, Megan Miller Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Alexa Kollmeier Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Elizabeth C Hsia Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Xie L Xu Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Miwa Izutsu Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Paraneedharan Ramachandran Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Shihong Sheng Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Yin You Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Philip Helliwell Consultant of: Galapagos, Janssen, Novartis, Grant/research support from: Abbvie, Janssen, Pfizer, Wolf-Henning Boehncke Speakers bureau: AbbVie, Almirall, Celgene, Janssen, Leo, Lilly, Novartis, and UCB Pharma, Consultant of: AbbVie, Almirall, Celgene, Janssen, Leo, Lilly, Novartis, and UCB Pharma, Grant/research support from: Pfizer

Style APA, Harvard, Vancouver, ISO itp.

38

Gottlieb, A. B., J. F. Merola, A. Armstrong, R. Langley, M. Lebwohl, C. E. M. Griffiths, M. Shawi i in. "AB0528 COMPARABLE SAFETY PROFILE OF GUSELKUMAB IN PSORIATIC ARTHRITIS AND PSORIASIS: RESULTS FROM PHASE 3 TRIALS THROUGH 1 YEAR". Annals of the Rheumatic Diseases 80, Suppl 1 (19.05.2021): 1293–94. http://dx.doi.org/10.1136/annrheumdis-2021-eular.556.

Pełny tekst źródła

Streszczenie:

Background:DISCOVER 1&2 (PsA) and VOYAGE 1&2 (PsO) are Phase 3 trials of guselkumab (GUS).Objectives:Compare safety results through up to 1yr of GUS in PsA and PsO pts.Methods:In DISCOVER, 1120 pts with active PsA despite standard therapy were treated. Most pts were biologic-naïve; ~30% in DISCOVER 1 had previous exposure to 1-2 TNFi. Concomitant MTX (57%), oral corticosteroids (17%), and NSAIDs (64%) were permitted. Pts were randomized to SC GUS 100mg at W0, W4, then Q8W; GUS 100mg Q4W; or PBO. At W24, PBO patients were switched to GUS 100mg Q4W. In VOYAGE, in which concomitant MTX use was prohibited, 1245 pts with moderate to severe PsO were treated and randomized to SC GUS 100 mg at W0, W4, W12, then Q8W; or PBO at W0, W4, W12, with crossover to GUS at W16, W20, then Q8W. AEs and laboratory parameters, analyzed by National Cancer Institute-Common Terminology Criteria for AEs [NCI-CTCAE] toxicity grades, were summarized through the PBO-controlled periods and 1yr.Results:Safety profiles were generally consistent across the GUS PsO and PsA clinical programs (Table 1). Time-adjusted incidence rates for numbers of AEs, serious AEs, serious infections, malignancy, MACE and AEs leading to d/c were generally similar between PsO and PsA. No cases of anaphylaxis or opportunistic infections were reported. Proportions of pts with decreased neutrophil counts and elevations in hepatic transaminases were slightly higher in PsA vs PsO. These abnormalities were mostly of NCI-CTCAE Grade 1 or 2 (<LLN-1000/mm3 for neutrophils; <5.0 x ULN for AST/ ALT), generally transient, required no medical interventions, resolved spontaneously, and did not lead to interruption or d/c of treatment. Through 1yr, proportions of pts with ALT/AST elevations in PsA trials were slightly higher for GUS Q4W than Q8W and in pts with vs without baseline MTX use.Conclusion:The GUS safety profile was generally consistent in PsA and PsO GUS-treated pts through 1yr of the DISCOVER and VOYAGE trials.Table 1.Treatment-Emergent AEs During PBO-controlled Period and Through 1Yr: VOYAGE & DISCOVER TrialsPooled VOYAGE 1&2Pooled DISCOVER 1&2Time PeriodW0-16Through 1YrW0-24bThrough 1Yr(N=)PBO(422)GUS Q8W(823)Combined GUSa(1221)PBOc(372)GUS Q8W(375)GUS Q4W (373)GUS Q8W(375)GUS Q4W (373)Combined GUS† (1100)Total pt-yrs of follow-up128255974173173172384385973Incidence/100 pt-yrs (95% CI)dAEs317 (287,349)330 (308,353)259 (249, 270)219 (198,243)256 (232,281)221 (200, 245)218 (203,233)177 (164,191)191 (182, 199)SAEs5 (2, 10)6 (4, 10)6 (5, 8)9 (5, 15)4 (2, 8)5 (2, 10)6 (4, 9)4 (2, 7)6 (4, 7)AEs leading to study agent d/c3 (0.9, 8)4 (2, 8)2 (2, 4)4 (2, 8)3 (1, 7)7 (4, 12)2 (1, 4)4 (2, 6)3 (2, 5)Infections86 (71, 104)98 (86, 111)98 (92, 104)58 (48, 71)58 (47, 71)63 (51, 76)58 (50, 66)53 (46, 61)55 (50, 60)Serious Infections0. 8 (0, 4)0.4 (0, 2)1 (0.5, 2)4 (2, 8)0.6 (0, 3)2 (0.4, 5)2 (0.6, 3)1 (0, 2)2 (0.9, 3)All Malignancy0 (0, 2)0.4 (0, 2)1 (0.4, 2)0.6 (0, 3)1 (0, 4)0 (0, 2)0.5 (0, 2)0 (0, 0. 8)0 (0, 1)MACE0 (0, 2)0.4 (0, 2)0.4 (0, 1)0.6 (0, 3)0 (0, 2)0.6 (0, 3)0 (0, 0.8)0.3 (0, 1.4)0.1 (0, 0.6)% pts with ≥1 injection site rxn3.14.55.00.31.31.11.62.41.7aPlacebo crossover pts were included in the combined GUS column after crossover to GUSbFor all pts who d/c study treatment early with the last dose of PBO/GUS prior to W24 and who did not receive any PBO/GUS at or after Wk24, all data including the final safety follow-up visit collected through 1yr were includedcFor pts in PBO group who switched to GUS due to cross-over or inadvertently, only data prior to first administration of GUS were included.dCI based on an exact method assuming observed number of events follows a Poisson distributionDisclosure of Interests:Alice B Gottlieb Consultant of: Anaptyps Bio, Avotres Therapeutics, Beiersdorf, Boehringer Ingelheim, Bristol-Myers-Squibb, Eli Lilly, Janssen, LEO Pharma, Novartis, Sun Pharmaceuticals, UCB, and Xbiotech, Grant/research support from: Boehringer Ingelheim, Janssen, Novartis, Sun Pharmaceuticals, UCB, and Xbiotech, Joseph F. Merola Consultant of: AbbVie, Arena, Biogen, BMS, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, UCB, April Armstrong Consultant of: AbbVie, Janssen, Lilly, Leo, Novartis, UCB, Ortho Dermatologics, Dermira, KHK, Sanofi, Regeneron, Sun Pharma, BMS, Dermavant, and Modernizing Medicine, Richard Langley Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, LEO Pharma, Merck, Novartis, Pizer, Sun Pharmaceutical, and UCB Pharma, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, LEO Pharma, Merck, Novartis, Pizer, Sun Pharmaceutical, and UCB Pharma, Mark Lebwohl Consultant of: Aditum Bio, Allergan, Almirall, Arcutis, Inc., Avotres Therapeutics, BirchBioMed Inc., BMD skincare, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Evommune, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy’s Laboratories, Serono, Theravance, and Verrica., Grant/research support from: Abbvie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly, Evommune, Incyte, Janssen, Leo Pharmaceutucals, Ortho Dermatologics, Pfizer, and UCB, Christopher E.M. Griffiths Speakers bureau: AbbVie, Amgen, Almirall, BMS, Boehringer Ingelheim Celgene, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sun Pharma, UCB Pharma., Consultant of: AbbVie, Amgen, Almirall, BMS, Boehringer Ingelheim Celgene, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sun Pharma, UCB Pharma., Grant/research support from: AbbVie, Amgen, Almirall, BMS, Boehringer Ingelheim Celgene, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sun Pharma, UCB Pharma., May Shawi Shareholder of: Johnson & Johnson, Employee of: Janssen Global Services, LLC, Ya-Wen Yang Shareholder of: Johnson & Johnson, Employee of: Janssen Global Services, LLC, Elizabeth C Hsia Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Alexa Kollmeier Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Xie L Xu Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Miwa Izutsu Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Paraneedharan Ramachandran Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Shihong Sheng Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Yin You Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Megan Miller Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Christopher T. Ritchlin Consultant of: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB Pharma, Grant/research support from: AbbVie, Amgen, and UCB Pharma, Iain McInnes Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, and Janssen, Novartis, Pfizer, and UCB, Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Proton Rahman Speakers bureau: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB, Grant/research support from: Janssen and Novartis.

Style APA, Harvard, Vancouver, ISO itp.

39

Mease, P. J., P. Foley, K. Reich, S. D. Chakravarty, M. Shawi, Y. W. Yang, M. Miller i in. "AB0892 Targeted Safety Analyses of Guselkumab: Long-Term Results from Randomized Clinical Trials in Patients with Active Psoriatic Arthritis and Moderate to Severe Psoriasis". Annals of the Rheumatic Diseases 81, Suppl 1 (23.05.2022): 1572–73. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1495.

Pełny tekst źródła

Streszczenie:

BackgroundGuselkumab (GUS) demonstrated efficacy and a favorable safety profile in active PsA in the Phase (Ph) 21 and Ph3 DISCOVER-1&2 trials2,3 and in moderate-to-severe plaque psoriasis (PsO) in the Ph3 VOYAGE-1&2 trials.4,5ObjectivesTo assess long-term safety of GUS across PsA/PsO trials.MethodsUsing pooled safety data through 2 years (yrs) from PsA trials (N=1229; GUS 100 mg every 4/8 weeks [Q4W/Q8W])1-3 and through 5 yrs from PsO trials (N=1721; GUS 100 mg Q8W),4,5 incidences of serious adverse events (SAEs); gastrointestinal (GI)-related SAEs and other targeted AEs; including candidiasis, uveitis, and opportunistic infections (OIs) were evaluated. Incidence rates (IRs) were calculated as the number of events per 100 pt-yrs (PY) of follow-up with 95% CI. Patients (pts) with an IBD history were not excluded in PsA/PsO trials. Max exposure duration was W100 for PsA trials and W252 for PsO trials.ResultsThe PsA and PsO populations had comparable mean age and BMI. IRs of SAEs and GI-related SAEs were generally similar between GUS- and PBO-treated pts during PBO-controlled periods, and between PsA pts receiving GUS Q4W/Q8W for up to 2 yrs and PsO pts receiving GUS Q8W for up to 5 yrs (Table 1). IRs of other targeted AEs of interest were low. OIs did not occur in PsO pts and were infrequent in PsA pts (Table 1). Candidal infections were infrequent and non-serious. Iridocyclitis was reported in 1 PBO- and 1 GUS Q8W-treated PsA pt. No exacerbations or new onset of IBD or active tuberculosis was reported in GUS-treated PsA/PsO pts.Table 1.Targeted AEs of InterestPooled PsA*Pooled PsOThrough 2 YrsThrough 5 YrsGUS 100 mg Q4W (N=373)GUS 100 mg Q8W (N=475)PBO→GUS 100 mg Q4W (N=352)aPBO→GUS 100 mg Q8W (N=29)aGUS Combined (N=1229)GUS 100 mg Q8W (N=1221)bADA→GUS 100 mg Q8W (N=500)cGUS Combined (N=1721)Total PY645748461171871525419127166Mean PY1.71.61.30.61.54.33.84.2Events/100 PY (95% CI)Overall SAEs4.65(3.14, 6.64)6.42(4.73, 8.51)5.86(3.86, 8.52)0.00(0.00, 17.24)5.61(4.59, 6.79)5.18(4.58, 5.83)4.55(3.64, 5.61)5.01(4.50, 5.56)GI-related SAEs0.46(0.10, 1.36)0.27(0.03, 0.97)0.00 (0.00, 0.65)0.00(0.00, 17.24)0.27(0.09, 0.62)0.44(0.28, 0.66)0.42(0.18, 0.82)0.43(0.29, 0.61)OIsd0.00(0.00, 0.46)0.27(0.03, 0.97)0.22(0.01, 1.21)0.00(0.00, 17.24)0.16(0.03, 0.47)0.00(0.00, 0.06)0.00(0.00, 0.16)0.00(0.00, 0.04)Candida infections0.31(0.04, 1.12)0.00(0.00, 0.40)0.00(0.00, 0.65)0.00(0.00, 17.24)0.11(0.01, 0.39)0.49(0.32, 0.73)0.52(0.25, 0.96)0.50(0.35, 0.70)Non-pathogen specific fungal infections, suspicious for candida0.00(0.00, 0.46)0.27(0.03, 0.97)0.00(0.00, 0.65)0.00(0.00, 17.24)0.11(0.01, 0.39)0.11(0.04, 0.25)0.16(0.03, 0.46)0.13(0.06, 0.24)Uveitis/ Iridocyclitis0.00(0.00, 0.46)0.13(0.00, 0.75)0.00(0.00, 0.65)0.00(0.00, 17.24)0.05(0.00, 0.30)0.00(0.00, 0.06)0.00(0.00, 0.16)0.00(0.00, 0.04)*In PsA Ph2, data after early escape at W16 were excluded. AEs are coded using MedDRA Version 23.1aFor PBO→GUS, data on/after 1st GUS administration were includedbPBO crossover pts were included in GUS column after crossover to GUScEvents prior to GUS (ADA events) were excluded. Only includes pts randomized to ADA at W0 and crossed over to GUS at/after W52 for VOYAGE-1 & W28 for VOYAGE-2dHerpes zoster disseminated, fungal oesophagitis, and meningitis listeria (1 each)ADA=AdalimumabConclusionIRs of SAEs; GI-related SAEs; and AEs of interest including candidiasis, uveitis, and OIs were low, or no cases were reported. No new safety concerns were identified with GUS treatment through 2 yrs and 5 yrs of follow-up in the pooled PsA and PsO trials, respectively, supporting a durable and favorable GUS safety profile consistent between pts with active PsA and moderate-to-severe PsO.References[1]Deodhar A, et al. Lancet. 2018;391:2213-2224.[2]Deodhar A, et al. Lancet. 2020;395:1115-1125.[3]Mease PJ, et al. Lancet. 2020;395:1126-1136.[4]Blauvelt A, et al. J Am Acad Dermatol. 2017;76:405-417.[5]Reich K, et al. J Am Acad Dermatol. 2017;76:418-431.Disclosure of InterestsPhilip J Mease Speakers bureau: AbbVie, Aclaris, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Celgene, Crescendo Bioscience, Genentech, Inmagene, Janssen, Lilly, Merck, Novartis, Pfizer, SUN Pharma, and UCB, Consultant of: AbbVie, Aclaris, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Celgene, Crescendo Bioscience, Genentech, Inmagene, Janssen, Lilly, Merck, Novartis, Pfizer, SUN Pharma, and UCB, Grant/research support from: AbbVie, Aclaris, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Celgene, Crescendo Bioscience, Genentech, Inmagene, Janssen, Lilly, Merck, Novartis, Pfizer, SUN Pharma, and UCB, Peter Foley Speakers bureau: AbbVie, Celgene, Janssen, Eli Lilly, Merck, Novartis, Pfizer, Valeant, Galderma, GlaxoSmithKline, Leo Pharma, and Roche, Paid instructor for: (Advisory boards) AbbVie, Amgen, Aslan, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Janssen, Eli Lilly, Merck, Novartis, Pfizer, Sun Pharma, UCB Pharma, Valeant, Galderma, GlaxoSmithKline, Leo Pharma, and Sanofi, Consultant of: Janssen, Eli Lilly, Novartis, Pfizer, UCB Pharma, Bristol-Myers Squibb, Galderma, Leo Pharma, and Roche; investigator for AbbVie, Amgen, AstraZeneca, Arcutis, Aslan, Boehringer Ingelheim, Celgene, Hexima, Janssen, Eli Lilly, Merck, Novartis, Pfizer, Sun Pharma, UCB Pharma, Valeant, Bristol-Myers Squibb, Celtaxsys, CSL, Cutanea, Dermira, Galderma, Genentech, GlaxoSmithKline, Leo Pharma, Regeneron Pharmaceuticals Inc, Reistone, Roche, and Sanofi, Grant/research support from: AbbVie, Amgen, Celgene, Janssen, Leo Pharma, Eli Lilly, Merck, Novartis, Pfizer, Sanofi, and Sun Pharma; travel grants from AbbVie, Janssen, Eli Lilly, Merck, Novartis, Pfizer, Galderma, Leo Pharma, Roche, Sun Pharma, and Sanofi; served as speaker for or received honoraria from AbbVie, Celgene, Janssen, Eli Lilly, Merck, Novartis, Pfizer, Valeant, Galderma, GlaxoSmithKline, Leo Pharma, and Roche, Kristian Reich Speakers bureau: Abbvie, Affibody, Amgen, Biogen, Boehringer Ingelheim Pharma, Bristol Myers Squibb, Celgene, Centocor, Covagen, Eli Lilly, Forward Pharma, Galderma, GlaxoSmithKline, Janssen-Cilag, Leo, Medac, Merck Sharp & Dohme Corp., Novartis, Ocean Pharma, Pfizer, Regeneron, Sanofi, Takeda, UCB Pharma, and Xenoport, Paid instructor for: Abbvie, Affibody, Amgen, Biogen, Boehringer Ingelheim Pharma, Bristol Myers Squibb, Celgene, Centocor, Covagen, Eli Lilly, Forward Pharma, Galderma, GlaxoSmithKline, Janssen-Cilag, Leo, Medac, Merck Sharp & Dohme Corp., Novartis, Ocean Pharma, Pfizer, Regeneron, Sanofi, Takeda, UCB Pharma, and Xenoport, Consultant of: Participated in clinical trials sponsored by Abbvie, Affibody, Amgen, Biogen, Boehringer Ingelheim Pharma, Bristol Myers Squibb, Celgene, Centocor, Covagen, Eli Lilly, Forward Pharma, Galderma, GlaxoSmithKline, Janssen-Cilag, Leo, Medac, Merck Sharp & Dohme Corp., Novartis, Ocean Pharma, Pfizer, Regeneron, Sanofi, Takeda, UCB Pharma, and Xenoport, Soumya D Chakravarty Employee of: Janssen Scientific Affairs, LLC and may own stock or stock options in Johnson & Johnson, May Shawi Employee of: Janssen Global Services, LLC and may own stock or stock options in Johnson & Johnson, Ya-Wen Yang Employee of: Janssen Global Services, LLC and may own stock or stock options in Johnson & Johnson, Megan Miller Employee of: Janssen Research & Development, LLC and may own stock or stock options in Johnson & Johnson, Alexa Kollmeier Employee of: Janssen Research & Development, LLC and may own stock or stock options in Johnson & Johnson, Xie L Xu Employee of: Janssen Research & Development, LLC and may own stock or stock options in Johnson & Johnson, Jenny Yu Employee of: Janssen Research & Development, LLC and may own stock or stock options in Johnson & Johnson, Yanli Wang Employee of: Janssen Research & Development, LLC and may own stock or stock options in Johnson & Johnson, Shihong Sheng Employee of: Janssen Research & Development, LLC and may own stock or stock options in Johnson & Johnson, Yin You Employee of: Janssen Research & Development, LLC and may own stock or stock options in Johnson & Johnson, Iain McInnes Consultant of: AbbVie, Bristol-Myers Squibb, Boehringer-Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis and UCB., Grant/research support from: Astra Zeneca, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Novartis, and UCB

Style APA, Harvard, Vancouver, ISO itp.

40

Thanh Huyen, Le, Dao Sy Duc, Nguyen Xuan Hoan, Nguyen Huu Tho i Nguyen Xuan Viet. "Synthesis of Fe3O4-Reduced Graphene Oxide Modified Tissue-Paper and Application in the Treatment of Methylene Blue". VNU Journal of Science: Natural Sciences and Technology 35, nr 3 (20.09.2019). http://dx.doi.org/10.25073/2588-1140/vnunst.4883.

Pełny tekst źródła

Streszczenie:

Graphene-based composites have received a great deal of attention in recent year because the presence of graphene can enhance the conductivity, strength of bulk materials and help create composites with superior qualities. Moreover, the incorporation of metal oxide nanoparticles such as Fe3O4 can improve the catalytic efficiency of composite material. In this work, we have synthesized a composite material with the combination of reduced graphene oxide (rGO), and Fe3O4 modified tissue-paper (mGO-PP) via a simple hydrothermal method, which improved the removal efficiency of the of methylene blue (MB) in water. MB blue is used as the model of contaminant to evaluate the catalytic efficiency of synthesized material by using a Fenton-like reaction. The obtained materials were characterized by SEM, XRD. The removal of materials with methylene blue is investigated by UV-VIS spectroscopy, and the result shows that mGO-PP composite is the potential composite for the color removed which has the removal efficiency reaching 65% in acetate buffer pH = 3 with the optimal time is 7 h. Keywords Graphene-based composite, methylene blue, Fenton-like reaction. References [1] Ma Joshi, Rue Bansal, Reng Purwar, Colour removal from textile effluents, Indian Journal of Fibre & Textile Research, 29 (2004) 239-259 http://nopr.niscair.res.in/handle/123456789/24631.[2] Kannan Nagar, Sundaram Mariappan, Kinetics and mechanism of removal of methylene blue by adsorption on various carbons-a comparative study, Dyes and pigments, 51 (2001) 25-40 https://doi.org/10.1016/S0143-7208(01)00056-0.[3] K Rastogi, J. N Sahu, B. C Meikap, M. N Biswas, Removal of methylene blue from wastewater using fly ash as an adsorbent by hydrocyclone, Journal of hazardous materials, 158 (2008) 531-540.https://doi.org/10.1016/j.jhazmat.2008.01. 105.[4] Qin Qingdong, Ma Jun, Liu Ke, Adsorption of anionic dyes on ammonium-functionalized MCM-41, Journal of Hazardous Materials, 162 (2009) 133-139 https://doi.org/10.1016/j.jhazmat. 2008.05.016.[5] Mui Muruganandham, Rps Suri, Sh Jafari, Mao Sillanpää, Lee Gang-Juan, Jaj Wu, Muo Swaminathan, Recent developments in homogeneous advanced oxidation processes for water and wastewater treatment, International Journal of Photoenergy, 2014 (2014). http://dx. doi.org/10.1155/2014/821674.[6] Herney Ramirez, Vicente Miguel , Madeira Luis Heterogeneous photo-Fenton oxidation with pillared clay-based catalysts for wastewater treatment: a review, Applied Catalysis B: Environmental, 98 (2010) 10-26 https://doi.org/ 10.1016/j.apcatb.2010.05.004.[7] Guo Rong, Jiao Tifeng, Li Ruifei, Chen Yan, Guo Wanchun, Zhang Lexin, Zhou Jingxin, Zhang Qingrui, Peng Qiuming, Sandwiched Fe3O4/carboxylate graphene oxide nanostructures constructed by layer-by-layer assembly for highly efficient and magnetically recyclable dye removal, ACS Sustainable Chemistry & Engineering, 6 (2017) 1279-1288 https://doi.org/10.1021/acssuschemeng.7b03635.[8] Sun Chao, Yang Sheng-Tao, Gao Zhenjie, Yang Shengnan, Yilihamu Ailimire, Ma Qiang, Zhao Ru-Song, Xue Fumin, Fe3O4/TiO2/reduced graphene oxide composites as highly efficient Fenton-like catalyst for the decoloration of methylene blue, Materials Chemistry and Physics, 223 (2019) 751-757 https://doi.org/ 10.1016/j.matchemphys.2018.11.056.[9] Guo Hui, Ma Xinfeng, Wang Chubei, Zhou Jianwei, Huang Jianxin, Wang Zijin, Sulfhydryl-Functionalized Reduced Graphene Oxide and Adsorption of Methylene Blue, Environmental Engineering Science, 36 (2019) 81-89 https://doi. org/10.1089/ees.2018.0157.[10] Zhao Lianqin, Yang Sheng-Tao, Feng Shicheng, Ma Qiang, Peng Xiaoling, Wu Deyi, Preparation and application of carboxylated graphene oxide sponge in dye removal, International journal of environmental research and public health, 14 (2017) 1301 https://doi.org/10.3390/ijerph14111301.[11] Yu Dandan, Wang Hua, Yang Jie, Niu Zhiqiang, Lu Huiting, Yang Yun, Cheng Liwei, Guo Lin, Dye wastewater cleanup by graphene composite paper for tailorable supercapacitors, ACS applied materials & interfaces, 9 (2017) 21298-21306 https://doi.org/10.1021/acsami.7b05318.[12] Wang Hou, Yuan Xingzhong, Wu Yan, Huang Huajun, Peng Xin, Zeng Guangming, Zhong Hua, Liang Jie, Ren MiaoMiao, Graphene-based materials: fabrication, characterization and application for the decontamination of wastewater and wastegas and hydrogen storage/generation, Advances in Colloid and Interface Science, 195 (2013) 19-40 https://doi. org/10.1016/j.cis.2013.03.009.[13] Marcano Daniela C, Kosynkin Dmitry V, Berlin Jacob M, Sinitskii Alexander, Sun Zhengzong, Slesarev Alexander, Alemany Lawrence B, Lu Wei, Tour James M, Improved synthesis of graphene oxide, ACS nano, 4 (2010) 4806-4814 https://doi.org/10.1021/nn1006368.[14] Zhang Jiali, Yang Haijun, Shen Guangxia, Cheng Ping, Zhang Jingyan, Guo Shouwu, Reduction of graphene oxide via L-ascorbic acid, Chemical Communications, 46 (2010) 1112-1114 http://doi. org/10.1039/B917705A [15] Gong Ming, Zhou Wu, Tsai Mon-Che, Zhou Jigang, Guan Mingyun, Lin Meng-Chang, Zhang Bo, Hu Yongfeng, Wang Di-Yan, Yang Jiang, Nanoscale nickel oxide/nickel heterostructures for active hydrogen evolution electrocatalysis, Nature communications, 5 (2014) 4695 https:// doi.org/10.1038/ncomms5695.[16] Wu Zhong-Shuai, Yang Shubin, Sun Yi, Parvez Khaled, Feng Xinliang, Müllen Klaus, 3D nitrogen-doped graphene aerogel-supported Fe3O4 nanoparticles as efficient electrocatalysts for the oxygen reduction reaction, Journal of the American Chemical Society, 134 (2012) 9082-9085 https://doi.org/10.1021/ja3030565.[17] Nguyen Son Truong, Nguyen Hoa Tien, Rinaldi Ali, Nguyen Nam Van, Fan Zeng, Duong Hai Minh, Morphology control and thermal stability of binderless-graphene aerogels from graphite for energy storage applications, Colloids and Surfaces A: Physicochemical and Engineering Aspects, 414 (2012) 352-358 https://doi.org/ 10.1016/j.colsurfa.2012.08.048.[18] Deng Yang, Englehardt James D, Treatment of landfill leachate by the Fenton process, Water research, 40 (2006) 3683-3694 https://doi.org/ 10.1016/j.watres.2006.08.009.

Style APA, Harvard, Vancouver, ISO itp.

41

ZHOU, RUONAN, ZIWEI ZHU, PINGYUAN XU, LIXUAN SHEN, ZIWEI WANG, YINGYING XUE, YINGYING XIANG i in. "2051-LB: Rhein Targets Macrophage SIRT2 to Promote Adipose Tissue Thermogenesis in Obesity". Diabetes 73, Supplement_1 (14.06.2024). http://dx.doi.org/10.2337/db24-2051-lb.

Pełny tekst źródła

Streszczenie:

Introduction & Objective: Rhein, a component derived from rhubarb as well as the active metabolite of the anti-osteoarthritis drug diacerein, has been proven to possess strong anti-inflammatory properties. However, the exact mechanism underlying the anti-inflammatory effects of rhein, and the role of rhein in ameliorating obesity remains unclear. Methods: Diet induced obese (DIO) mice were employed to observe the effects of rhein on metabolism. A macrophage-adipocyte co-culture system was constructed to elucidate the exact mechanism underlying the beneficial effect of rhein on metabolism. Acetylome analysis was performed to screen the acetylation-modifying enzymes regulated by rhein. Surface plasmon resonance assay was used to verify the interaction between rhein and SIRT2. Lyz2-iCre mice injected with rAAV-DIO-shSirt2 were used to verify the durg target of rhein in vivo. PBMCs from patients with obesity receiving diacerein or placebo treatment were collected for acetylation assay. Results: Rhein mitigated obesity by promoting white adipose tissue thermogenesis in DIO mice, and rhein promoted adipocyte thermogenesis through inhibiting the activation of NLRP3 inflammasome in macrophages. Further study proved that rhein directly interacts with SIRT2 and inhibits NLRP3 inflammasome activation in a SIRT2-dependent way. Myeloid knockdown of Sirt2 abrogated the metabolic benefits induced by rhein in DIO mice. PBMCs from patients with obesity receiving diacerein treatment had significant lower level of acetylation than those from the placebo group. Conclusion: Rhein promotes adipose tissue thermogenesis by targeting SIRT2 to regulate acetylation-mediated NLRP3 inflammasome activation in macrophages during obesity. Rhein and its derivatives may become potential drug for treating obesity. Disclosure R. Zhou: None. Z. Zhu: None. P. Xu: None. L. Shen: None. Z. Wang: None. Y. Xue: None. Y. Xiang: None. Y. Cao: None. X. Yu: None. J. Yu: None. J. Zhao: None. J. Yan: None. Q. Yang: None. P. Fang: None. W. Shang: None. Funding National Natural Science Foundation of China (81873060, 81473391 and 82374100); Priority Academic Program Development of Jiangsu Higher Education Institutions (ZYX03KF058); Graduate Research and Innovation Projects of Jiangsu Province (KYCX23_2133 and SJCX23_0728).

Style APA, Harvard, Vancouver, ISO itp.

42

Li, Hsin-Hua, Hanoch Livneh, Wei-Jen Chen, Wen-Lin Fan, Ming-Chi Lu, How-Ran Guo i Tzung-Yi Tsai. "Effect of Chinese Herbal Medicines on Hearing Loss Risk in Rheumatoid Arthritis Patients: Retrospective Claims Analysis". Frontiers in Medicine 8 (20.07.2021). http://dx.doi.org/10.3389/fmed.2021.683211.

Pełny tekst źródła

Streszczenie:

Objectives: Patients with rheumatoid arthritis (RA) are at a higher risk of extra-articular manifestations, especially hearing loss (HL). Although Chinese herbal medicines (CHM) are proven safe and effective treatments for inflammatory conditions, the effect of CHM use on HL in RA patients is unknown. This cohort study aims to determine the relationship between CHM use and the subsequent risk of HL among RA patients.Methods: From health insurance claims data in Taiwan, a total of 6,905 persons aged 20–80 years with newly-diagnosed RA in 2000–2009 were identified. Of these, we recruited 2,765 CHM users and randomly selected 2,765 non-CHM users who matched with the users by the propensity score. Both cohorts were followed up until the end of 2012 to estimate the incidence of HL. Cox proportional hazards regression was used to estimate the adjusted hazard ratio (HR) for HL.Results: The incidence of HL was lower in the CHM users than in the comparison cohort (8.06 vs. 10.54 per 1,000 person-years) (adjusted HR, 0.77; 95% CI, 0.63–0.94). Those who received CHM for more than 2 years had the greatest benefit against the onset of HL, with over 50% risk reduction. Prescriptions of Hai Piao Xiao, Yan Hu Suo, San-Qi, Huang Qin, Dang Shen, Jia-Wei-Xiao-Yao-San, Shu-Jing-Huo-Xue-Tang, and Dang-Gui-Nian-Tong-Tang were found to be associated with a reduced risk of HL.Conclusions: Our findings suggest that adding CHM to conventional therapy may reduce the subsequent risk of HL in RA patients. Prospective randomized trials are recommended to further clarify whether the association revealed in this study supports such a causal relationship.

Style APA, Harvard, Vancouver, ISO itp.

43

Ibrahim, Michael Ibrahim, Maria Joseph Bassil, Umit B. Demirci, Georges El Hajj Moussa, Vincent Salles, Mario Remond El Tahchi i Philippe Miele. "Photovoltaic Properties of Polyaniline-Titania Composite for Hybrid Solar Cells Applications". MRS Proceedings 1211 (2009). http://dx.doi.org/10.1557/proc-1211-r03-18.

Pełny tekst źródła

Streszczenie:

AbstractSolar energy harvesting has been extensively studied in the last three decades to provide a green energy source. Hybrid photovoltaics (HPV) based on titania (TiO2) are researched for their easiness of production and low cost. Nanostructured mesoporous titania films and conductive polymers were used recently to form hybrid solar cells [1]. TiO2, mainly an n-type semiconductor with a band gap of 4.2 eV, is employed in several applications from which paints form the highest world use of titania making it an attractive material to use in HPV industry. On the other side, our targeted conductive polymer is polyaniline (PANI), a hole conductor polymer, which is used in such HPV cells due to its high charge-carriers mobility, absorption coefficient in the visible range and environmental stability. PANI and nanocrystalline TiO2 films fabricated using spin coating or layer by layer assembly techniques behave as a p-n heterojunction diode and can be used as solar cells [2-4].Precursor solutions are prepared by polymerizing aniline-HCl inside an aqueous solution of titania. To study the effect of the precursor concentration on the PANI-TiO2 composite, polymerization of aniline is held in diverse TiO2 concentrations in water. Industrial grade TiO2 powders with particle size ranging from 200 nm to several μm are used. PANI-TiO2 precursor solutions are dip coated or slot dyed on various substrates such as PMMA, PET and PP, all with metal oxide conductive coatings. Bulk PANI-TiO2 pellets are prepared for comparison. The electrical and photovoltaic properties of the obtained films and pellets are investigated to choose the optimum blend composition for HPV cell. Finally a theoretical study and an analytical model of the HPV cell are presented relating the size of TiO2 and PANI particles and their respective geometrical distribution inside the blend to the transport characteristics of charge carriers and the overall efficiency of the HPV cell.[1] M. McGehee, MRS Bulletin, Vol. 34, No. 2, February 2009.[2] Z. Liu, W. Guo, D. Fu and W. Chen, Synthetic Metals, Vol. 156, pp. 414–416, 2006.[3] Z. Liu, J. Zhou, H. Xue, L. Shen, H. Zang and W. Chen, Synthetic Metals, Vol. 156, pp. 721–723, 2006.[4] X. Zhang, G. Yan, H. Ding and Y. Shan, Materials Chemistry and Physics, Vol. 102, pp. 249–254, 2007.

Style APA, Harvard, Vancouver, ISO itp.

44

Thinh, Nguyen Hong, Tran Hoang Tung i Le Vu Ha. "Depth-aware salient object segmentation". VNU Journal of Science: Computer Science and Communication Engineering 36, nr 2 (7.10.2020). http://dx.doi.org/10.25073/2588-1086/vnucsce.217.

Pełny tekst źródła

Streszczenie:

Object segmentation is an important task which is widely employed in many computer vision applications such as object detection, tracking, recognition, and retrieval. It can be seen as a two-phase process: object detection and segmentation. Object segmentation becomes more challenging in case there is no prior knowledge about the object in the scene. In such conditions, visual attention analysis via saliency mapping may offer a mean to predict the object location by using visual contrast, local or global, to identify regions that draw strong attention in the image. However, in such situations as clutter background, highly varied object surface, or shadow, regular and salient object segmentation approaches based on a single image feature such as color or brightness have shown to be insufficient for the task. This work proposes a new salient object segmentation method which uses a depth map obtained from the input image for enhancing the accuracy of saliency mapping. A deep learning-based method is employed for depth map estimation. Our experiments showed that the proposed method outperforms other state-of-the-art object segmentation algorithms in terms of recall and precision. KeywordsSaliency map, Depth map, deep learning, object segmentation References[1] Itti, C. Koch, E. Niebur, A model of saliency-based visual attention for rapid scene analysis, IEEE Transactions on pattern analysis and machine intelligence 20(11) (1998) 1254-1259.[2] Goferman, L. Zelnik-Manor, A. Tal, Context-aware saliency detection, IEEE transactions on pattern analysis and machine intelligence 34(10) (2012) 1915-1926.[3] Kanan, M.H. Tong, L. Zhang, G.W. Cottrell, Sun: Top-down saliency using natural statistics, Visual cognition 17(6-7) (2009) 979-1003.[4] Liu, Z. Yuan, J. Sun, J. Wang, N. Zheng, X. Tang, H.-Y. Shum, Learning to detect a salient object, IEEE Transactions on Pattern analysis and machine intelligence 33(2) (2011) 353-367.[5] Perazzi, P. Krähenbühl, Y. Pritch, A. Hornung, Saliency filters: Contrast based filtering for salient region detection, in: Computer Vision and Pattern Recognition (CVPR), 2012 IEEE Conference on, IEEE, 2012, pp. 733-740.[6] M. Cheng, N.J. Mitra, X. Huang, P.H. Torr, S.M. Hu, Global contrast based salient region detection, IEEE Transactions on Pattern Analysis and Machine Intelligence 37(3) (2015) 569-582.[7] Borji, L. Itti, State-of-the-art in visual attention modeling, IEEE transactions on pattern analysis and machine intelligence 35(1) (2013) 185-207.[8] Simonyan, A. Vedaldi, A. Zisserman, Deep inside convolutional networks: Visualising image classification models and saliency maps, arXiv preprint arXiv:1312.6034.[9] Li, Y. Yu, Visual saliency based on multiscale deep features, in: Proceedings of the IEEE conference on computer vision and pattern recognition, 2015, pp. 5455-5463.[10] Liu, J. Han, Dhsnet: Deep hierarchical saliency network for salient object detection, in: Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition, 2016, pp. 678-686.[11] Achanta, S. Hemami, F. Estrada, S. Susstrunk, Frequency-tuned saliency detection model, CVPR: Proc IEEE, 2009, pp. 1597-604.Fu, J. Cheng, Z. Li, H. Lu, Saliency cuts: An automatic approach to object segmentation, in: Pattern Recognition, 2008. ICPR 2008. 19th International Conference on, IEEE, 2008, pp. 1-4Borenstein, J. Malik, Shape guided object segmentation, in: Computer Vision and Pattern Recognition, 2006 IEEE Computer Society Conference on, Vol. 1, IEEE, 2006, pp. 969-976.Jiang, J. Wang, Z. Yuan, T. Liu, N. Zheng, S. Li, Automatic salient object segmentation based on context and shape prior., in: BMVC. 6 (2011) 9.Ciptadi, T. Hermans, J.M. Rehg, An in depth view of saliency, Georgia Institute of Technology, 2013.Desingh, K.M. Krishna, D. Rajan, C. Jawahar, Depth really matters: Improving visual salient region detection with depth., in: BMVC, 2013.Li, J. Ye, Y. Ji, H. Ling, J. Yu, Saliency detection on light field, in: Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition, 2014, pp. 2806-2813.Koch, S. Ullman, Shifts in selective visual attention: towards the underlying neural circuitry, in: Matters of intelligence, Springer, 1987, pp. 115-141.Laina, C. Rupprecht, V. Belagiannis, F. Tombari, N. Navab, Deeper depth prediction with fully convolutional residual networks, in: 3D Vision (3DV), 2016 Fourth International Conference on, IEEE, 2016, pp. 239-248.Bruce, J. Tsotsos, Saliency based on information maximization, in: Advances in neural information processing systems, 2006, pp. 155-162.Ren, X. Gong, L. Yu, W. Zhou, M. Ying Yang, Exploiting global priors for rgb-d saliency detection, in: Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition Workshops, 2015, pp. 25-32.Fang, J. Wang, M. Narwaria, P. Le Callet, W. Lin, Saliency detection for stereoscopic images., IEEE Trans. Image Processing 23(6) (2014) 2625-2636.Hou, L. Zhang, Saliency detection: A spectral residual approach, in: Computer Vision and Pattern Recognition, 2007. CVPR’07. IEEE Conference on, IEEE, 2007, pp. 1-8.Guo, Q. Ma, L. Zhang, Spatio-temporal saliency detection using phase spectrum of quaternion fourier transform, in: Computer vision and pattern recognition, 2008. cvpr 2008. ieee conference on, IEEE, 2008, pp. 1-8.Fang, W. Lin, B.S. Lee, C.T. Lau, Z. Chen, C.W. Lin, Bottom-up saliency detection model based on human visual sensitivity and amplitude spectrum, IEEE Transactions on Multimedia 14(1) (2012) 187-198.Lang, T.V. Nguyen, H. Katti, K. Yadati, M. Kankanhalli, S. Yan, Depth matters: Influence of depth cues on visual saliency, in: Computer vision-ECCV 2012, Springer, 2012, pp. 101-115.Zhang, G. Jiang, M. Yu, K. Chen, Stereoscopic visual attention model for 3d video, in: International Conference on Multimedia Modeling, Springer, 2010, pp. 314-324.Wang, M.P. Da Silva, P. Le Callet, V. Ricordel, Computational model of stereoscopic 3d visual saliency, IEEE Transactions on Image Processing 22(6) (2013) 2151-2165.Peng, B. Li, W. Xiong, W. Hu, R. Ji, Rgbd salient object detection: A benchmark and algorithms, in: European Conference on Computer Vision (ECCV), 2014, pp. 92-109.Wu, L. Duan, L. Kong, Rgb-d salient object detection via feature fusion and multi-scale enhancement, in: CCF Chinese Conference on Computer Vision, Springer, 2015, pp. 359-368.Xue, Y. Gu, Y. Li, J. Yang, Rgb-d saliency detection via mutual guided manifold ranking, in: Image Processing (ICIP), 2015 IEEE International Conference on, IEEE, 2015, pp. 666-670.Katz, A. Adler, Depth camera based on structured light and stereo vision, uS Patent App. 12/877,595 (Mar. 8 2012).Chatterjee, G. Molina, D. Lelescu, Systems and methods for determining depth from multiple views of a scene that include aliasing using hypothesized fusion, uS Patent App. 13/623,091 (Mar. 21 2013).Matthies, T. Kanade, R. Szeliski, Kalman filter-based algorithms for estimating depth from image sequences, International Journal of Computer Vision 3(3) (1989) 209-238.Y. Schechner, N. Kiryati, Depth from defocus vs. stereo: How different really are they?, International Journal of Computer Vision 39(2) (2000) 141-162.Delage, H. Lee, A.Y. Ng, A dynamic bayesian network model for autonomous 3d reconstruction from a single indoor image, in: Computer Vision and Pattern Recognition, 2006 IEEE Computer Society Conference on, Vol. 2, IEEE, 2006, pp. 2418-2428.Saxena, M. Sun, A.Y. Ng, Make3d: Learning 3d scene structure from a single still image, IEEE transactions on pattern analysis and machine intelligence 31(5) (2009) 824-840.Hedau, D. Hoiem, D. Forsyth, Recovering the spatial layout of cluttered rooms, in: Computer vision, 2009 IEEE 12th international conference on, IEEE, 2009, pp. 1849-1856.Liu, S. Gould, D. Koller, Single image depth estimation from predicted semantic labels, in: Computer Vision and Pattern Recognition (CVPR), 2010 IEEE Conference on, IEEE, 2010, pp. 1253-1260.Ladicky, J. Shi, M. Pollefeys, Pulling things out of perspective, in: Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition, 2014, pp. 89-96.K. Nathan Silberman, Derek Hoiem, R. Fergus, Indoor segmentation and support inference from rgbd images, in: ECCV, 2012.Liu, J. Yuen, A. Torralba, Sift flow: Dense correspondence across scenes and its applications, IEEE transactions on pattern analysis and machine intelligence 33(5) (2011) 978-994.Konrad, M. Wang, P. Ishwar, 2d-to-3d image conversion by learning depth from examples, in: Computer Vision and Pattern Recognition Workshops (CVPRW), 2012 IEEE Computer Society Conference on, IEEE, 2012, pp. 16-22.Liu, C. Shen, G. Lin, Deep convolutional neural fields for depth estimation from a single image, in: Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition, 2015, pp. 5162-5170.Wang, X. Shen, Z. Lin, S. Cohen, B. Price, A.L. Yuille, Towards unified depth and semantic prediction from a single image, in: Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition, 2015, pp. 2800-2809.Geiger, P. Lenz, C. Stiller, R. Urtasun, Vision meets robotics: The kitti dataset, International Journal of Robotics Research (IJRR).Achanta, S. Süsstrunk, Saliency detection using maximum symmetric surround, in: Image processing (ICIP), 2010 17th IEEE international conference on, IEEE, 2010, pp. 2653-2656.E. Rahtu, J. Kannala, M. Salo, J. Heikkilä, Segmenting salient objects from images and videos, in: Computer Vision-ECCV 2010, Springer, 2010, pp. 366-37.

Style APA, Harvard, Vancouver, ISO itp.

45

Van Dem, Pham, Pham Trung Kien, Nguyen Thanh Trung, Nguyen Thu Huong, Nguyen Thanh Nam, Pham Quang Tue i Tran Minh Dien. "Clinical, Paraclinical Characteristics and Relative Risk Factors of Severe Degree in Children with COVID-19: Systematic Review". VNU Journal of Science: Medical and Pharmaceutical Sciences 38, nr 1 (24.03.2022). http://dx.doi.org/10.25073/2588-1132/vnumps.4371.

Pełny tekst źródła

Streszczenie:

Aim: systematic review of studies in the medical literature of children with COVID – 19 in order to provide evidence of clinical, paraclinical characteristics and relative risk factors of severe degree in children with COVID-19. Research subjects: A systematic review of studies on COVID-19 in children published in the international medical literature. Research methods: the information of research reports was selected from information posted on the COVID-19 update reporting portal of the Ministry of Health, PubMed, EMBASE, Cochrane Library, WHO COVID-19 Database, China National Knowledge Infrastructure (CNKI) Database, WanFang Database through system overview. Results: we collected 115 studies related to COVID-19 in children, published from January 2020 to August 2021, and by screening, we selected 21 studies related to clinical, paraclinical characteristics and relative risk factors of severe degree in children with COVID-19. Keywords: Variant Delta, COVID-19 in children, Clinical, Paraclinical Characteristics and risk factors of severe degree. References [1] Minnistry of Health, Dayly Recorded of COVID-19 (in Vietnamese), https://www.moh.gov.vn/ (accessed on: August 31st, 2021).[2] World Health Organization, Clinical Management Severe Acute Respiratory Infection when Novel Coronavirus (2019-nCoV) Infection is Suspected: Interim Guidance, 2020, 28 January 2020, pp. 1-10.[3] CDC (Centers for Disease Control and Prevention), COVID-19 Response Team, Coronavirus Disease 2019 in Children-United States, February 12-April 2, 2020, MMWR Morb Mortal Wkly Rep, 2020, Vol. 69, No, 14, pp. 422-426, https://doi.org/10. 15585/mmwr.mm6914e4.[4] J. F. Ludvigsson, Systematic review of COVID-19 in Children Shows Milder Cases and a Better Prognosis than Adults, Acta Paediatr, 2020 Jun, Vol. 109, No. 6, pp. 1088-1095, https://doi.org/10.1111.[5] CDC (Centers for Disease Control and Prevention), US COVID-19 Cases caused by Variants, Up-to-Date Info: https://www.cdc.gov/coronavirus/2019-nCoV (accessed on: August 31st, 2021).[6] N. Parri, M. L. D. Buonsenso, Children with Covid-19 in Pediatric Emergency Departments in Italy, N Engl J Med, 2020, Vol. 383, No. 2, pp. 187-190, https://doi.org/10.1056/NEJMc2007617, 2020. [7] Q. Lu and Y. Shi, Coronavirus Disease (COVID-19) and Neonate: what Neonatologist Need to Know, J Med Virol, 2020, Vol. 92, No. 6 , pp. 564-567, https://doi.org/10.1002/jmv.25740. [8] H. Tezer and T. B. Demirdrag, Novel Coronavirus Disease (COVID-19) in Children, Turk J Med Sci, 2020, Vol 50, pp. 592-603, https://doi.org/10.3906/sag-2004-17, 2020.[9] L. K. Zeng, X. W. Tao, W. H. Yuan et al., First Case of Neonate Infected with Novel Coronavirus Pneumonia in China. Front. Pediatr, 2020, Vol. 8, pp. 1-8, https://doi.org/10.3389/fped.2020.00287. [10] M. Wei, J. Yuan, Y. Liu et al., Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. JAMA, 2020, Vol. 323, No. 13, pp. 1313-1314, https://doi.org /10.1001/jama.2020.2131. [11] D. Wang, X. L. Ju, F. Xie et al., Clinical Analysis of 31 Cases of 2019 Novel Coronavirus Infection in Children from Six Provinces (Autonomous Region) of Northern China, Zhonghua Er Ke Za Zhi, 2020, Vol. 58, No. 4, pp. 269-274, https://doi.org/10.3760/cma.j.cn112140-20200225-00138, 2020. [12] S. Tiana, N. Hub, J. Lou et al., Characteristics of COVID-19 Infection in Beijing, J Infect, 2020, Vol. 80, No. 4, pp. 401-406, https://doi.org/10.1016/j.jinf.2020.02.018. [13] H. Zhu, L. Wang, C. Fang et al., Clinical Analysis of 10 Neonates Born to Mothers with 2019-nCoV Pneumonia. Transl Pediatr, 2020, Vol. 9, pp. 51-60, https://doi.org/10.21037/tp.2020.02.06. [14] Y. Dong, X. Mo, Y. Hu et al., Epidemiological Characteristics of 2143 Pediatric Patients with 2019 Coronavirus Disease in China, J Emerg Med, 2020, Vol . 58, No. 4, pp. 712-713, https://doi.org/1016/j.jemermed.2020.04.006. [15] I. Liguoro, C. Pilotto, M. Bonann et al., SARS-COV-2 Infection in Children and Newborns: A Systematic Review. SARS-COV-2 Infection in Children and Newborns: A Systematic Review, European Journal of Pediatrics, 2020, Vol. 18, 2020, pp. 1-18, https://doi.org/10.1007/s00431-020-03684-7. [16] J. Yasuhara, T. Kuno, H. Takagi, Clinical Characteristics of COVID‐19 in Children: A Systematic Review, Pediatric Pulmonology, 2020, Vol. 55, No. 10, pp. 2565-2575, https://doi.org/10.1002/ppul.24991. [17] T. H. D. Souza, J. A. Nadal, R. J. N. Nogueira et al., Clinical Manifestations of Children with COVID-19: A Systematic Review, Pediatr Pulmonol, 2021, Vol. 55, No. 8, pp. 1892-1899, https://doi.org/ 10.1002/ppul.24885. [18] Q. Shen, W. Guo, T. Guo et al., Novel Coronavirus Infection in Children Outside of Wuhan, China, Pediatr Pulmonol, 2020, Vol. 55, No. 6, pp. 1424-1429, https://doi.org/10.1002/ppul.24762. [19] H. Qiu, J.a Wu, L. Hong et al., Clinical and Epidemiological Features of 36 Children with Coronavirus Disease 2019 (COVID-19) in Zhejiang, China: an Observational Cohort Study, Lancet Infect Dis, 2020, Vol. 20, No. 6, pp. 689-696, https://doi.org/10.1016/S1473-3099(20)30198-5. [20] N. M. Mustafaa, L. A. Selimc, Characterisation of COVID-19 Pandemic in Paediatric Age Group: A Systematic Review and Meta-Analysis, J Clin Virol, 2020, Vol. 128, pp. 1-15, https://doi.org/10.1016/j.jcv.2020.104395. [21] W. Guan, Z. Y. Ni, Y. Hu et al., Clinical Characteristics of 2019 Novel Coronavirus Infection in China, 2020, N Engl J Med, Vol. 382, pp. 1708-1720, https://doi.org/10.1056/NEJMoa2002032.

Style APA, Harvard, Vancouver, ISO itp.

46

"Force field of tetrafluoroborate anion for molecular dynamics simulation: a new approach". Kharkov University Bulletin Chemical Series, nr 33 (2019). http://dx.doi.org/10.26565/2220-637x-2019-33-03.

Pełny tekst źródła

Streszczenie:

González A., Goikolea E., Barrena J. A., Mysyk R. Review on supercapacitors: Technologies and materials. Renew. Sustain. Energy Rev. 2016, 58 1189-1206. Zhong C., Deng Y., Hu W., Qiao J., Zhang L., Zhang J. A review of electrolyte materials and compositions for electrochemical supercapacitors. Chem. Soc. Rev. 2015, 44 (21), 7484-7539. Dahl K., Sando G., Fox D., Sutto T., Owrutsky J. Vibrational spectroscopy and dynamics of small anions in ionic liquid solutions. J. Chem. Phys. 2005, 123 084504. Zhang B., Yuan Z., li X., Ren X., Nian H., Shen Y., Yun Q. Ion-molecule interaction in solutions of lithium tetrafluoroborate in propylene carbonate: An ftir vibrational spectroscopic study. In. J. Electrochem. Sc. 2013, 8 12735-12740. Jow T. R., Xu K., Borodin O., Ue M. Electrolytes for lithium and lithium-ion batteries. Springer: New York, NY, 2014; Vol. 58, p 476. Paschoal V. H., Faria L. F. O., Ribeiro M. C. C. Vibrational spectroscopy of ionic liquids. Chem. Rev. 2017, 117 (10), 7053-7112. Ueno S., Tanimura Y., Ten-no S. Molecular dynamics simulation for infrared spectroscopy with intramolecular forces from electronic properties of on-the-fly quantum chemical calculations. Int. J. Quantum Chem. 2013, 113 (3), 330-335. Xu R. J., Blasiak B., Cho M., Layfield J. P., Londergan C. H. A direct, quantitative connection between molecular dynamics simulations and vibrational probe line shapes. J. Phys. Chem. Lett. 2018, 9 (10), 2560-2567. Choi E., Yethiraj A. Conformational properties of a polymer in an ionic liquid: Computer simulations and integral equation theory of a coarse-grained model. J. Phys. Chem. B 2015, 119 (29), 9091-9097. Li B., Ma K., Wang Y.-L., Turesson M., Woodward C. E., Forsman J. Fused coarse-grained model of aromatic ionic liquids and their behaviour at electrodes. Phys. Chem. Chem. Phys. 2016, 18 (11), 8165-8173. Mehta N. A., Levin D. A. Molecular dynamics electrospray simulations of coarse-grained ethylammonium nitrate (ean) and 1-ethyl-3-methylimidazolium tetrafluoroborate (EMIM-BF4). Aerospace 2018, 5 (1). Son C. Y., McDaniel J. G., Schmidt J. R., Cui Q., Yethiraj A. First-principles united atom force field for the ionic liquid Bmim+BF4–: An alternative to charge scaling. J. Phys. Chem. B 2016, 120 (14), 3560-3568. Tetiana C., Oleg K., Yaroslav K. Microstructure and dynamics of single charged ions in propylene carbonate. Kharkov Univ. Bull. Chem. Ser. 2013, 0 (22), 25-38. Vovchynskyi I. S., Kolesnik Y. V., Filatov Y. I., Kalugin O. N. Molecular modelling on solutions of 1-1′-spirobipirrolidinium tetrafluoroborate in acetonitrile. J. Mol. Liq. 2017, 235 60-67. Sambasivarao S. V., Acevedo O. Development of opls-aa force field parameters for 68 unique ionic liquids. J. Chem. Theory Comput. 2009, 5 (4), 1038-1050. Doherty B., Zhong X., Gathiaka S., Li B., Acevedo O. Revisiting OPLS force field parameters for ionic liquid simulations. J. Chem. Theory Comput. 2017, 13 (12), 6131 6145. Feng G., Huang J., Sumpter B. G., Meunier V., Qiao R. Structure and dynamics of electrical double layers in organic electrolytes. Phys. Chem. Chem. Phys. 2010, 12 (20), 5468-5479. Kanzaki R., Mitsugi T., Fukuda S., Fujii K., Takeuchi M., Soejima Y., Takamuku T., Yamaguchi T., Umebayashi Y., Ishiguro S.-i. Ion–ion interaction in room temperature ionic liquid 1-ethyl-3-methylimidazolium tetrafluoroborate studied by large angle x-ray scattering experiment and molecular dynamics simulations. J. Mol. Liq. 2009, 147 (1), 77-82. Shim Y., Kim H. J. Nanoporous carbon supercapacitors in an ionic liquid: A computer simulation study. ACS Nano 2010, 4 (4), 2345-2355. Shim Y., Jung Y., Kim H. J. Graphene-based supercapacitors: A computer simulation study. J. Phys. Chem. B 2011, 115 (47), 23574-23583. Yang P.-Y., Ju S.-P., Hsieh H.-S., Lin J.-S. The diffusion behavior and capacitance of tetraethylammonium/tetrafluoroborate ions in acetonitrile with different molar concentrations: A molecular dynamics study. RSC Adv. 2017, 7 (87), 55044-55050. Zhang Q.-Y., Xie P., Wang X., Yu X.-W., Shi Z.-Q., Zhao S.-H. Thermodynamic and transport properties of spiro-(1,1')-bipyrrolidinium tetrafluoroborate and acetonitrile mixtures: A molecular dynamics study. Chin. Phys. B 2016, 25 (6), 066102. Liu Z., Huang S., Wang W. A refined force field for molecular simulation of imidazolium-based ionic liquids. J. Phys. Chem. B 2004, 108 (34), 12978-12989. Wu X., Liu Z., Huang S., Wang W. Molecular dynamics simulation of room-temperature ionic liquid mixture of [Bmim][BF4] and acetonitrile by a refined force field. Phys. Chem. Chem. Phys. 2005, 7 (14), 2771-2779. de Andrade J., Böes E. S., Stassen H. Computational study of room temperature molten salts composed by 1-alkyl-3-methylimidazolium cationsforce-field proposal and validation. J. Phys. Chem. B 2002, 106 (51), 13344-13351. Canongia Lopes J. N., Pádua A. A. H. Molecular force field for ionic liquids iii: Imidazolium, pyridinium, and phosphonium cations; chloride, bromide, and dicyanamide anions. J. Phys. Chem. B 2006, 110 (39), 19586-19592. Frisch M. J., Trucks G. W., Schlegel H. B., Scuseria G. E., Robb M. A., Cheeseman J. R., Scalmani G., Barone V., Petersson G. A., Nakatsuji H., Li X., Caricato M., Marenich A. V., Bloino J., Janesko B. G., Gomperts R., Mennucci B., Hratchian H. P., Ortiz J. V., Izmaylov A. F., Sonnenberg J. L., Williams, Ding F., Lipparini F., Egidi F., Goings J., Peng B., Petrone A., Henderson T., Ranasinghe D., Zakrzewski V. G., Gao J., Rega N., Zheng G., Liang W., Hada M., Ehara M., Toyota K., Fukuda R., Hasegawa J., Ishida M., Nakajima T., Honda Y., Kitao O., Nakai H., Vreven T., Throssell K., Montgomery Jr. J. A., Peralta J. E., Ogliaro F., Bearpark M. J., Heyd J. J., Brothers E. N., Kudin K. N., Staroverov V. N., Keith T. A., Kobayashi R., Normand J., Raghavachari K., Rendell A. P., Burant J. C., Iyengar S. S., Tomasi J., Cossi M., Millam J. M., Klene M., Adamo C., Cammi R., Ochterski J. W., Martin R. L., Morokuma K., Farkas O., Foresman J. B., Fox D. J. Gaussian 16 rev. C.01, Wallingford, CT, 2016. Breneman C. M., Wiberg K. B. Determining atom-centered monopoles from molecular electrostatic potentials. The need for high sampling density in formamide conformational analysis. J. Comput. Chem. 1990, 11 (3), 361-373. Cornell W. D., Cieplak P., Bayly C. I., Gould I. R., Merz K. M., Ferguson D. M., Spellmeyer D. C., Fox T., Caldwell J. W., Kollman P. A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117 (19), 5179-5197. Mayo S. L., Olafson B. D., Goddard W. A. Dreiding: A generic force field for molecular simulations. J. Phys. Chem. 1990, 94 (26), 8897-8909. Schmidt M. W., Baldridge K. K., Boatz J. A., Elbert S. T., Gordon M. S., Jensen J. H., Koseki S., Matsunaga N., Nguyen K. A., Su S., Windus T. L., Dupuis M., Montgomery Jr J. A. General atomic and molecular electronic structure system. J. Comput. Chem. 1993, 14 (11), 1347-1363. Xue H., Twamley B., Shreeve J. n. M. The first 1-alkyl-3-perfluoroalkyl-4,5- dimethyl-1,2,4-triazolium salts. J. Org. Chem. 2004, 69 (4), 1397-1400. Jorgensen W. L., Maxwell D. S., Tirado-Rives J. Development and testing of the opls all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 1996, 118 (45), 11225-11236. Pádua A. A. H., Costa Gomes M. F., Canongia Lopes J. N. A. Molecular solutes in ionic liquids: A structural perspective. Acc. Chem. Res. 2007, 40 (11), 1087-1096. Pensado A. S., Gomes M. F. C., Lopes J. N. C., Malfreyt P., Pádua A. A. H. Effect of alkyl chain length and hydroxyl group functionalization on the surface properties of imidazolium ionic liquids. Phys. Chem. Chem. Phys. 2011, 13 (30), 13518-13526. Shimizu K., Pensado A., Malfreyt P., Pádua A. A. H., Canongia Lopes J. N. 2d or not 2d: Structural and charge ordering at the solid-liquid interface of the 1 (2 hydroxyethyl)-3-methylimidazolium tetrafluoroborate ionic liquid. Faraday Discuss. 2012, 154 (0), 155-169. Canongia Lopes J. N., Deschamps J., Pádua A. A. H. Modeling ionic liquids using a systematic all-atom force field. J. Phys. Chem. B 2004, 108 (6), 2038-2047. Canongia Lopes J. N., Pádua A. A. H. Molecular force field for ionic liquids composed of triflate or bistriflylimide anions. J. Phys. Chem. B 2004, 108 (43), 16893 16898. Shimizu K., Almantariotis D., Gomes M. F. C., Pádua A. A. H., Canongia Lopes J. N. Molecular force field for ionic liquids v: Hydroxyethylimidazolium, dimethoxy-2- methylimidazolium, and fluoroalkylimidazolium cations and bis(fluorosulfonyl)amide, perfluoroalkanesulfonylamide, and fluoroalkylfluorophosphate anions. J. Phys. Chem. B 2010, 114 (10), 3592-3600. Smith W., Yong C. W., Rodger P. M. DL_POLY: Application to molecular simulation. Mol. Simulat. 2002, 28 (5), 385-471. Lindahl E., Hess B., van der Spoel D. Gromacs 3.0: A package for molecular simulation and trajectory analysis. J. Mol. Model. 2001, 7 (8), 306-317. Pronk S., Páll S., Schulz R., Larsson P., Bjelkmar P., Apostolov R., Shirts M. R., Smith J. C., Kasson P. M., van der Spoel D., Hess B., Lindahl E. Gromacs 4.5: A high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 2013, 29 (7), 845-854. Van Der Spoel D., Lindahl E., Hess B., Groenhof G., Mark A. E., Berendsen H. J. C. GROMACS: Fast, flexible, and free. J. Comput. Chem. 2005, 26 (16), 1701-1718. Bussi G., Donadio D., Parrinello M. Canonical sampling through velocity rescaling. J. Chem. Phys. 2007, 126 (1), 014101. Berendsen H. J. C., Postma J. P. M., van Gunsteren W. F., DiNola A., Haak J. R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 1984, 81 (8), 3684-3690. Koverga V. A., Korsun O. M., Kalugin O. N., Marekha B. A., Idrissi A. A new potential model for acetonitrile: Insight into the local structure organization. J. Mol. Liq. 2017, 233 251-261. Agieienko V. N., Kolesnik Y. V., Kalugin O. N. Structure, solvation, and dynamics of Mg2+, Ca2+, Sr2+, and Ba2+ complexes with 3-hydroxyflavone and perchlorate anion in acetonitrile medium: A molecular dynamics simulation study. J. Chem. Phys. 2014, 140 (19), 194501. Kovacs H., Kowalewski J., Maliniak A., Stilbs P. Multinuclear relaxation and nmr self-diffusion study of the molecular dynamics in acetonitrile-chloroform liquid mixtures. J. Phys. Chem. 1989, 93 (2), 962-969. Kunz W., Calmettes P., Bellissent-Funel M. C. Dynamics of liquid acetonitrile at high frequencies. J. Chem. Phys. 1993, 99 (3), 2079-2082. Hurle R. L., Woolf L. A. Self-diffusion in liquid acetonitrile under pressure. J. Chem. Soc. Faraday Trans. 1982, 78 (7), 2233-2238. Hawlicka E., Grabowski R. Solvation of ions in acetonitrile-methanol solutions of sodium iodide. Ber. Bunsenges. Phys. Chern. 1990, 94 (4), 486-489. Holz M., Mao X. a., Seiferling D., Sacco A. Experimental study of dynamic isotope effects in molecular liquids: Detection of translationrotation coupling. J. Chem. Phys. 1996, 104 (2), 669-679. Liang M., Zhang X.-X., Kaintz A., Ernsting N. P., Maroncelli M. Solvation dynamics in a prototypical ionic liquid + dipolar aprotic liquid mixture: 1-butyl-3-methylimidazolium tetrafluoroborate + acetonitrile. J. Phys. Chem. B 2014, 118 (5), 1340-1352. Marcus Y. The properties of solvents. 1998. Marekha B. A., Kalugin O. N., Bria M., Buchner R., Idrissi A. Translational diffusion in mixtures of imidazolium ils with polar aprotic molecular solvents. J. Phys. Chem. B 2014, 118 (20), 5509-5517. Bešter-Rogač M., Stoppa A., Buchner R. Ion association of imidazolium ionic liquids in acetonitrile. J. Phys. Chem. B 2014, 118 (5), 1426-1435.

Style APA, Harvard, Vancouver, ISO itp.

47

Reis, Bruna de Oliveira, Glívia Queiroz Lima, Ana Teresa Maluly-Proni, Henrico Badaoui Strazzi Sahyon, Thaís Yumi Umeda Suzuki, Marco Aurélio de Lima Vidotti, Erik Neiva Ribeiro de Carvalho Reis, Eduardo Passos Rocha, Wirley Gonçalves Assunção i Paulo Henrique Dos Santos. "Desenvolvimento clínico e estágio atual da odontologia adesiva". ARCHIVES OF HEALTH INVESTIGATION 8, nr 6 (13.09.2019). http://dx.doi.org/10.21270/archi.v8i6.3808.

Pełny tekst źródła

Streszczenie:

Introdução: O maior foco das pesquisas odontológicas nos últimos 60 anos tem sido a adesão e suas técnicas. Mais de 7000 artigos já foram publicados a este respeito. O desenvolvimento dos materiais odontológicos adesivos e as técnicas a eles relacionadas possuem uma história interessante, onde descobertas do passado ainda são usadas de alguma forma no presente. Objetivo: expor, através de uma revisão de literatura, um breve histórico sobre materiais e técnicas restauradoras, bem como o estágio atual da odontologia adesiva, com ênfase na tradução de evidências baseadas em pesquisas laboratoriais para a prática clínica. Materiais e Métodos: Foram selecionados livros de preferência do autor para a introdução de conceitos clássicos e artigos de revisão publicados nos últimos 10 anos, utilizando as cinco palavras-chave: “Dental Bonding” AND “Dental Cements” AND “Resin Cements” AND “Adhesives” AND “Ceramics”, sorteados pela melhor combinação na plataforma Pub/Med/MEDLINE. Resultados: Duzentos e um artigos, foram encontrados, sendo utilizados para análise qualitativa e quantitativa aqueles pertinentes ao direcionamento do autor, de acordo com o tema. Conclusão: Considerando as limitações do estudo, concluiu-se que a odontologia adesiva é uma área que segue em constante desenvolvimento, fundamental para a realização de restaurações minimamente invasivas e estéticas. Onde para que seja possível consequentemente longevidade clínica, os materiais utilizados e substrato dentário requerem conhecimento do profissional e fidelidade na execução de um correto pré-tratamento das superfícies, respeitando suas naturezas e composições.Descritores: Colagem Dentária; Cimentos Dentários; Cimentos de Resina; Adesivos; Cerâmica.ReferênciasVan Meerbeek B, De Munck J, Yoshida Y, Inoue S, Vargas M, Vijay P, et al. Buonocore memorial lecture. Adhesion to enamel and dentin: current status and future challenges. Oper Dent. 2003;28:215-35.Miyashita E, Fonseca AS. Odontologia Estética: O estado da arte. São Paulo: Artes Médicas; 2004.Hagger O. Swiss Patent 27894 British Patent 687299, 1951.Buonocore MG, Willeman W, Brudevold F. A Report on a resin composition capable of bonding to human dentin surface. J Dent Res. 1956;35:846-51.Bottino MA, Faria R, Valandro LF. Percepção: estética em próteses livres de metal em dentes naturais e implantes. São Paulo: Artes Médicas, 2009.Larson TD. Using multiple bonding strategies. northwest dent. 2015;94:33-9.Helvey GA. Adhesive dentistry: the development of immediate dentin sealing/selective etching bonding technique. Compend Contin Educ Dent. 2011;32:22,24-32,34-5.Hashimoto M, Ohno H, Kaga M, Endo K, Sano H, Oguchi H. In vivo degradation of resin-dentin bonds in humans over 1 to 3 years. J Dent Res. 2000;79:1385-91.Mante FK, Ozer F, Walter R, Atlas AM, Saleh N, Dietschi D, et al. The current state of adhesive dentistry: a guide for clinical practice. Compend Contin Educ Dent. 2013;34:2-8.Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med. 2009;3:e123-30.Bento A. Como fazer uma revisão de literatura: Considerações teóricas e práticas. Revista JA (Associação Acadêmica da Universidade da Madeira). 2012;65:42-4.Gwinnett AJ. Structure and composition of enamel. Oper Dent. 1992;5:10-7.Mondelli J, Furuse AY, Francischone AC, Pereira MA. Excelência estética e funcional das resinas compostas em dentes posteriores. São Paulo: Artes Médicas; 2004.Garberoglio R, Bränström M. Scanning electron microscopy investigation of human dentinal tubules. Arch Oral Biol. 1976;21:355-62.Pashley DH. Dentin, a dynamic substrate – A review. Scanning Microscopy. 1989;1:161-74.Mazzoni A, Mannello F, Tay FR, Tonti GA, Mazzotti G, Di Lenarda R et al. Zymographic analysis and characterization of MMP-2 and -9 forms in human sound dentin. J Dent Res. 2007;86:436-40.Mankovskaia A, Lévesque CM, Prakki A. Catechin-incorporated dental copolymers inhibit growth of Streptococcus mutans. J Appl Oral Sci. 2013;21:203-7.Sulkala M, Larmas M, Sorsa T, Salo T, Tjäderhane L. The localization of matrix metalloproteinase-20 (MMP-20, enamelysin) in mature human teeth. J Dent Res. 2002;81:603-7.Tjaderhane L, Palosaari H, Wahlgren J, Larmas M, Sorsa T, Salo T. Human odontoblast culture method: the expression of collagen and matrix metalloproteinases (MMPs). Adv Dent Res. 2001;15:55-8.Wang DY, Zhang L, Fan J, Li F, Ma KQ, Wang P, et al. Matrix metalloproteinases in human sclerotic dentine of attrited molars. Arch Oral Biol. 2012;57:1307-12.Wang Y, Spencer P, Walker MP. Chemicalprofileof adhesive/caries-affected dentin interfaces using Raman microspectroscopy. J Biomed Mat Res. 2007;81A:279-86.Suppa P, Ruggeri A Jr, Tay FR, Prati C, Biasotto M, Falconi M, et al. Reduced antigenicity of type I collagen and proteoglycans in sclerotic dentin. J Dent Res. 2006;85:133-37.Madfa AA, Yue XG. Dental protheses mimic the natural enamel behavior under functional loading: A review article. Jpn Dent Sci Rev. 2016;52:2-13.Nakabayashi N, Pashley DH. Hybridization of Dental Hard Tissues. Tokio: Quintessence Publishing, 1998.Van Meerbeek B, Vargas M, Inoue S, Yoshida Y, Peumans M, Lambrechts P, et al. Adhesives and cements to promote preservation dentistry. Oper Dent. 2001;6:119-44.Pashley DH, Carvalho RM. Dentine permeability and dentine adhesion. J Dent. 1997;25:355-72.Imazato S, Tarumi H, Ebi N, Ebisu S. Citotoxic effects of composite restorations employing self-etching primers or experimental antibacterial primers. J Dent. 2000;28:61-7.Alex G. Universal adhesives: the next evolution in adhesive dentistry? Compend Contin Educ Dent. 2015;36:15-26.Muñoz MA, Luque I, Hass V, Reis A, Loguercio AD, Bombarda NH. Immediate bonding properties of universal adhesives to dentine. Journal of Dentistry. 2013;41:404–11.Pashley DH, Tay FR. Aggressiveness of contemporary self-etching adhesives Part II: Etching effects on unground enamel. Dental Mater. 2001;17:430-44.Rosa WL, Piva E, Silva AF. Bond strength of universal adhesives: A systematic review and meta-analysis. J Dent. 2015;43:765-76.Szesz A, Parreiras S, Reis A, Loguercio A. Selective enamel etching in cervical lesions for self-etch adhesives: A systematic review and meta-analysis. J Dent. 2016;53:1-11.Kord FP, Lee BP. Recent approches in designing bioadhesive materials inspired by mussel adhesive protein. J Polym Sci A Polym Chem. 2017;55:9-33.Peters MC, McLean ME. Minimally Invasive Operative Care I. Minimal Intervention and Concepts for Minimally Invasive Cavity Preparations. J Ad Dent. 2011;3:7-16.Tyas MJ, Anusavice KJ, Frencken JE, Mount GJ. Minimal Intervention Dentistry – A review. Int Dent J. 2000;50:1-12.Roulet JF, Wilson NHF, Fuzzi M. Advances in Operative Dentistry – Contemporary clinical Practice. Oxford: Quintessence Books, 2000.Najeeb S, Khurshid Z, Zafar MS, Khan AS, Zohaib S, Martí JM, et al. Modifications in Glass Ionomer Cements: Nano-Sized Fillers and Bioactive Nanoceramics. Int J Mol Sci. 2016;17:pii:E1134.Poubel DLN, Almeida JCF, Dias Ribeiro AP, Maia GB, Martinez JMG, Garcia FCP. Effect of dehydration and rehydration intervals on fracture resistance of reattached tooth fragments using multimode adhesive. Dent Traumatol. 2017;33:451-7.Mainjot AK, Dupont NM, Oudkerk JC, Dewael TY, Sadoun MJ. From Artisanal to CAD-CAM Blocks: State of the Art of Indirect Composites. J Dent Res. 2016;95:487-95.Lacy AM. A critical look at posterior composite restorations. J Am Dent Assoc. 1987;114:357-62.Anusavice KJ. Phillips’ Science of dental materials: 11th ed. Philadelphia: W.B, 2003.Bella Dona A. Adesão às cerâmicas: evidências científicas para o uso clínico. São Paulo: Artes Médicas, 2009.Fairhurst CW. Dental ceramics: the state of the Science. Adv Dent Res. 1992;6:78-81.Kurdvk B. Giuseppangelo Fonzi: Industrial fabrication promoter of porcelain prosthetics. J History Dent. 1999;47:79-82.Jones DW, Wilson HJ. Some properties of dental ceramics. J Oral Rehabil. 1975;2:379-96.Messer RL, Lockwood PE, Wataha JC, Lewis JB, Norris S, Bouillaguet S. In vitro cytotoxicity of traditional versus contemporary dental ceramics. J Prosthet Dent. 2003;90:452-58.Zarone F, Ferrari M, Mangano FG, Leone R, Sorrentino R. Digitally oriented materials: focus on lithium disilicate ceramics. Int J Dent. 2016:9840594.Shen Z, Nygren M. Microstructural prototyping of ceramics by Kinect engineering: applications of spark plasma sintering. Chem Rec. 2005;5:173-84.Denry I, Kelly JR. Emerging ceramic-based materials for dentistry. J Dent Res. 2014;93: 1235-42.Baier RE. Principles of adhesion. Oper Dent. 1992;5:1-9.Erickson RL. Surface interactions of dentin adhesive materials. Oper Dent. 1992;5:81-94.Ruyter, IE. The chemistry of adhesive agents. Oper Dent. 1992;5-11.Jendresen MD, Glantz PO, Baier RE, Eick JD. Microtopography and clinical adhesiveness of an acid etched tooth surface. An vivo study. Acta Odontolol Scand. 1981;39:47-53.Van Meerbeek B, Perdigão J, Lambrechts P, Vanherie G. The Clinical performance adhesives. J Dent Res. 1998;26:1-20.De Munck J, Van Landuyt K, Peumans M, Poitevin A, Lambrechts P, Braem M, et al. A critical review of the durability of adhesion to tooth tissue: methods and results. J Dent Res. 2005;84:118-32.Matei R, Popescu MR, Suciu M, Rauten AM. Clinical dental adhesive application: the influence on composite-enamel interface morphology. Rom J Morphol Embryol. 2014;55:863-68.Buonocore MG. A simple method of increasing the adhesion of acrylic filling materials to enamel surfaces. J Dent Res. 1955;34:849-53.Chow LC, Brown, WE. Phosphoric acid conditioning of teeth for pit and fissure sealants. J Dent Res. 1973;1517-25.Bastos PA, Retief DH, Bradley EL, Denys FR. Effect of duration on the shear bond strength of a microfill composite resin to enamel. Am J Dent. 1988;1:151-57.Gwinnett AJ. Acid etching for composite resins. Dent Clin North Amer. 1981;25:271-89.Retief DH. Are adhesives techniques suficiente to prevent microleakage? Symposium of Dental Materials, Pulp Biology Group, IADR, The Netherlands. 1986.Causton BE. Improved bonding of composite restorative to dentin. Br Dent J. 1984;156:93-5.Mitchen JC, Gronas DG. Effects of time after extraction and depth of dentin on resin dentin adhesives. J Am Dent Ass. 1986;113:285-89.Heymann HO, Bayne SC. Current concepts in dentin bonding: focusing in dentin adhesion factors. J Am Dent Ass. 1993;124:27-36.Dbradović-Djuricić K, Medić V, Dodić S, Gavrilov D, Antonijević D, Zrilić M. Dilemmas in zirconia bonding: a review. Srp Arh Celok Lek. 2013;141:395-401.Chen C, Chen Y, Lu Z, Qian M, Xie H, Tay FR. The effects of water on degradation of the zirconia-resin bond. J Dent. 2017;pii: S0300-5712, 17, 30088-X.Naumova EA, Ernst S, Schaper K, Arnold WH, Piwowarczyk A. Adhesion of different resin cements to enamel and dentin. Dent Mater J. 2016;35:345-52.Novais VR, Rapouso LH, Miranda RR, Lopes CC, Simamoto PC Júnior, Soares CJ. Degree of conversion and bond strength of resin-cements to feldspathic ceramic using different curing modes. J Appl Oral Sci. 2017;25:61-8.Giannini M, Takagaki T, Bacelar-Sá R, Vermelho PM, Ambrosano GMB, Sadr A et al. Influence of resin coating on bond strength of self-adhesive resin cements to dentin. Dent Mat J. 2015;34:822-7.Ferracane JL, Stansbury JW, Burke FJ. Self-adhesive resin cements —chemistry, properties and clinical considerations. J Oral Rehabil. 2011; 38:295-314.De Munck J, Vargas M, Van Landuyt K, Hikita K, Lambrechts P, Van Meerbeek B. Bonding o fan auto-adhesive luting material to enamel and dentin. Dent Mater. 2004;20:963-71.Abo-Hamar SE, Hiller KA, Jung H, Federlin M, Friedl KH, Schmalz G. Bond strength of a new universal self-adhesive resin lutin cement to dentin and enamel. Clin Oral Invest. 2005;9:161-7.Aguiar TR, Di Francescantonio M, Ambrosano GM, Giannini M. Effect of curing mode on bod strength of self-adhesive resin luting cements to dentin. J Biomed Mater Res B Appl Biomater. 2010;93B:122-7.Asmussen E, Peutzeldt A. Bonding of dual-curing resin cements to dentin. J Adhes Dent. 2006;8:299-304.Cantoro A, Goracci C, Papacchini F, Mazzitelli C, Fadda GM, Ferrari M. Effect of pre-cure temperature on the bonding potential of self-etch and self-adhesive resin cements. Dent Mater. 2008;24:577-83.76.Hitz T, Stawarczyk B, Fischer J, Hämmerle CH, Sailer I. Are self-sdhesive resin cement a valid alternative to conventional resin cements? A laboratory study of the long-term bond strength. Dent Mater. 2012;28:1183-90.Özcan M, Bernasconi M. Adhesion to zirconia used for dental restorations: a systematic review and meta-analysis. J Adhes Dent. 2015;17:7-26.Ganapathy D, Sathyamoorthy A, Ranganathan H, Murthykumar K. Effect of resin bonded luting agents influencing marginal discrepancy in all ceramic complete veneer crowns. J Clin Diagn Res. 2016;10:ZC67-ZC70.Lorenzoni E Silva F, Pamato S, Kuga MC, Só MV, Pereira JR. Bond strength of adhesive resin cement with different adhesive systems. J Clin Exp Dent. 2017;9:96-100.Spitznagel FA, Horvath SD, Guess PC, Blatz MB. Resin bond to indirect composite and new ceramic/polymer materials: a review of the literature. J Esthet Restor Dent. 2014;26:382-93.

Style APA, Harvard, Vancouver, ISO itp.

Artykuły w czasopismach na temat „Sheng yun xue”

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych